

**Prognostic markers in breast cancer analysed by lectin stainings,  
immunocytochemistry and flow cytometry**

Leena Krogerus

Pathology Laboratory,

Helsinki University Hospital, Helsinki, Finland

Academic Dissertation

Helsinki 2001

To be publicly discussed , with the permission of the Faculty of Medicine of the  
University of Helsinki, in the Small Lecture Hall of Haartman Institute,  
Haartmaninkatu 3, Helsinki, on August 31<sup>st</sup> , at noon.

HELSINKI 2001



**This thesis was supervised by**

**Professor Leif Andersson**

Pathology Laboratory

University of Helsinki and Helsinki University Hospital

**Reviewed by**

**Docent Paula Martikainen**

University of Tampere

and

**Docent Ylermi Soini**

University of Oulu

**Opponent at the Dissertation**

**Professor Mårten Fernö**

Onkology Unit

University of Lund

ISBN 952-91-3679-X (Printed version.)

ISBN 952-10-0083-X (PDF version, [www.ethesis.fi](http://www.ethesis.fi))

## Table of contents

<b>TABLE OF CONTENTS.....</b>	<b>4</b>
<b>1 LIST OF ORIGINAL PUBLICATIONS.....</b>	<b>5</b>
<b>2 ABBREVIATIONS.....</b>	<b>6</b>
<b>3 INTRODUCTION.....</b>	<b>8</b>
<b>4 REVIEW OF THE LITERATURE.....</b>	<b>10</b>
4.1 BREAST CANCER INCIDENCE IN FINLAND.....	10
4.2 SCREENING FOR BREAST CANCER.....	10
4.3 DIAGNOSIS OF BREAST CANCER.....	11
4.3.1 <i>FNA and CNB</i> .....	11
4.3.2 <i>Radiography of tissue removed</i> .....	12
4.3.3 <i>Frozen section</i> .....	13
4.3.4 <i>Final pathology reports</i> .....	13
4.4 PROGNOSIS OF BREAST CANCER.....	14
4.4.1 <i>Classical prognostic markers</i> .....	14
4.4.2 <i>Other histological criteria of breast cancer</i> .....	17
4.5 PATIENT-RELATED PROGNOSTIC MARKERS.....	20
4.5.1 <i>Age of the patient</i> .....	20
4.5.2 <i>Diet and life-style</i> .....	21
4.6 MOLECULAR PROGNOSIS MARKERS OF BREAST CANCER.....	22
4.6.1 <i>Genetics of breast cancer</i> .....	22
4.6.2 <i>Immunohistochemical characterisation of tumours</i> .....	26
4.6.3 <i>Lectin staining for tumour characterisation</i> .....	26
4.6.4 <i>Hormone receptors as markers for differentiation and hormone dependency</i> .....	27
4.6.5 <i>Kinetics of breast cancer</i> .....	29
4.6.6 <i>Oncogen products in breast cancer</i> .....	31
4.6.7 <i>Adhesion</i> .....	36
4.6.8 <i>Metastasis</i> .....	39
4.7 TREATMENT OF BREAST CANCER.....	40
<b>5 AIMS OF THE STUDY.....</b>	<b>41</b>
<b>6 MATERIALS AND METHODS.....</b>	<b>42</b>
6.1 TUMOUR GRADING AND TYPING.....	43
6.2 LECTIN HISTOCHEMISTRY.....	43
6.3 IMMUNOHISTOCHEMISTRY (IHC).....	44
6.4 FLOW CYTOMETRY.....	47
6.4 STATISTICAL ANALYSIS.....	49
<b>7 RESULTS.....</b>	<b>50</b>
7.1 FNA:STUDYIII.....	50
7.2 LECTIN STAINING: STUDY I.....	51
7.3 PROLIFERATIVE EPITHELIAL LESIONS: STUDY V.....	51
7.4 ADVANCED BREAST CANCER: STUDY II.....	53
<b>8 DISCUSSION.....</b>	<b>54</b>
<b>9 SUMMARY AND CONCLUSIONS.....</b>	<b>61</b>
<b>10 ACKNOWLEDGEMENTS.....</b>	<b>62</b>
<b>11 REFERENCES.....</b>	<b>63</b>

## **1 List of original publications**

This thesis is based on the following original publications:

- I. **Krogerus L, Andersson LC: Different lectin-binding patterns in primary breast cancers and their metastases. *Cancer* 66:1802-9, 1990**
- II **Leivonen M, Krogerus L, Nordling S: DNA analysis in advanced breast cancer. *Cancer Detection & Prevention* 18:87-96, 1994**
- III. **Krogerus LA, Railo M, Schoultz M, and Nordling S: Flow cytometric DNA measurements in aspiration biopsies and surgical specimens of breast cancer. *Analytical & Quantitative Cytology & Histology* 17:309-13, 1995**
- IV. **Krogerus L, Leivonen M: HER-2/neu in advanced breast cancer. *Cancer Detection & Prevention* 25:1-7, 2001**
- V. **Krogerus L, Leivonen M, Hästö A-L: Expression patterns of biologic markers in small breast cancers and preneoplastic breast lesions: *The Breast* 9:281-5, 2000**

## 2 Abbreviations

ADH	Atypical ductal hyperplasia
CD	Cluster of differentiation
CGH	Comparative genomic hybridisation
CNB	Core needle biopsy
ConA	Concanavalin A
CV	Coefficient of variation
DBA	Dolichos biflorus agglutinin
DC	Ductal carcinoma
DCIS	Ductal carcinoma in situ
DI	DNA index
EGFR	Epidermal growth factor receptor
ER	Oestrogen receptor
FISH	Fluorescence in situ hybridisation
FITC	Fluorescein isothiocyanate
FNA and FNAB	Fine needle aspiration biopsy
HPA	Helix pomatia agglutinin
IHC	Immunohistochemistry
LC	Lobular carcinoma

LCIS	Lobular carcinoma in situ
LOH	Loss of heterozygosity
mAb	Monoclonal antibody
NPI	Nottingham prognostic index
PNA	Peanut agglutinin
PR	Progesteron receptor
RCA	Ricinus communis agglutinin
SLN	Sentinel lymph node biopsy
SPF	Synthesis phase fraction
UEAI	Ulex europaeus agglutinin
WGA	Wheat germ agglutinin

### 3 Introduction

Breast cancer is the most frequent malignancy of Finnish women leading to death (Registry 1996). Once locally excised, some breast cancers are cured, while others progress rapidly or leading to death even after staying dormant for many years.

This difference in the behaviour of the tumours can not be foreseen by morphological criteria alone (Silvestrini et al. 1995). Reliable prediction of the course of the disease has thus far not been possible, despite constant attempts (McGuire and Clark 1992; Moss et al. 1994). With the advent of new investigative methods based on molecular biology, the cancer cells can be more accurately characterised, and perhaps targeted by new specific therapeutic agents (Neville et al. 1992; Silvestrini et al. 1993; Silvestrini et al. 1994).

Cancer treatment has become more effective, but also more expensive. Besides different kinds of surgical procedures, oncologists now use hormones and antihormones (Harris et al. 1992), radiotherapy (Lavin et al. 1994; Meyn et al. 1996), many kinds of chemotherapy (Neville et al. 1992), and immunotherapy (Voelker 2000). Profound knowledge of the specific properties of tumours provides an opportunity to tailor individual cancer treatment for each patient (Neville et al. 1992).



With the emergence of screening for breast cancer also premalignant diseases are found (Murphy et al. 1995). Their malignant potential is variable, and the follow-up of these patients may be problematic (Kerlikowske et al. 1995). Knowledge of the recurrence risk in different diseases may save the patient undue anxiety and the community unnecessary costs.

The established markers for a favourable prognosis in breast cancer are the absence of lymph node metastasis (Toikkanen and Joensuu 1990), small tumour size (Toikkanen and Joensuu 1990), and low histological grade (Blamey et al. 1979; Bloom and Richardson 1957; Toikkanen and Joensuu 1990). Some selected histological types of breast cancer, such as mucinous carcinoma, have also been found to behave in a more benign fashion than other types of cancer (Toikkanen and Kujari 1989).

This study attempted to identify further characteristics of breast tumours useful for the oncologists in their selection of treatment methods. The means were: Lectin staining and flow cytometric analyses of advanced breast cancer, both primary tumours and their metastases. Flow cytometry was done from fine needle aspiration biopsies (FNAB) and tissue samples of malignant tumours, and the accuracy of these different diagnostic methods was compared. Finally, immunohistochemistry (IHC) of small,unpalpable breast cancers and known premalignant lesions was done with a panel of seven antibodies related to cell proliferation and cell death.

## 4 Review of the literature

### ***4.1 Breast cancer incidence in Finland***

The incidence of breast cancer in Finland has grown steadily during the 1980s, and outnumbered the incidence of cancer of the digestive tract in the beginning of the 90s (Registry 1996). Although the cumulative five-year survival rate with modern therapy (1985-1989 in Finland) was 79% (Registry 1996), this disease leads to about 1870 deaths annually (1997). Of these women, 24% are still below 50 years of age at the time of diagnosis (Registry 1996) making the loss for the society even greater. Finding means for at least extending their survival is worthwhile.

### ***4.2 Screening for breast cancer***

One of the most important prognostic markers is tumour size (Joensuu and Toikkanen 1991; Rosen et al. 1992). Detection of the cancer at an early stage is therefore believed to be essential. This is the philosophy behind the national breast cancer screening programmes instituted in many Western countries. Efficient screening has been claimed to reduce breast cancer mortality (Antman and Shea 1999; Kerlikowske et al. 1995; Miller et al. 2000; Nyström et al. 1993; Senie et al. 1994). Critics, however, have claimed that screening finds the wrong cancers, i.e. those that would not be fatal anyway (Groenendijk et al. 2000; Kallioniemi et al. 1989; Kleini et al. 1992). The screening of large populations is associated with socio-economic side effects, e.g. anxiety in the screened population. We therefore have to know what we are looking for, and how to deal with the findings.

So far, the only method to find breast cancer when the tumour is smaller than 1cm in diameter, and still not palpable, is mammography (Antman and Shea 1999).

Mammography is not an absolute tool, however. It may fail when the breast tissue is very fibrotic (Lam et al. 2000; Mandelson et al. 2000), as it often is in young women, and in those receiving hormonal replacement therapy (Lam et al. 2000). It also fails if done too infrequently. Also, some types of tumours are difficult to see on the mammograms (Porter et al. 2000; Silverstein et al. 1994). Young women have to have screening mammograms taken at shorter intervals in order for the screening to be effective. This has a negative psychological effect on the healthy women targeted, and is one reason why some countries have not started screening programmes for breast cancer (Cockburn et al. 1994). The death rate due to breast cancer in such countries is nevertheless increasing (Antman and Shea 1999), while it is not in countries with an effective screening programme (Nyström et al. 1993). One conclusion to be drawn from the recent data is, that participation in screening programmes is a favourable prognostic factor (Antman and Shea 1999).

The Canadian National Breast screening study has, however, shown that annual screening with skilled physical examination alone, with the teaching of breast self-examination is as effective as mammography in reducing breast cancer deaths (Miller et al. 2000). This result is valid regardless of the fact that the tumours and their axillary metastases are larger in size at the time of diagnosis than the tumours detected by mammography.

### ***4.3 Diagnosis of breast cancer***

#### **4.3.1 FNA and CNB**

When a breast lump or parenchymal change is palpated or seen on a mammogram, a tissue sample, either cytological (FNA) (Bondesson and Lindholm 1997; Masood 1995; Wilkinson and Hendricks 1993) or histological (CNB) (Gajdos et

al. 1999; Sharifi et al. 1999) is taken. The pathologists estimate whether there are malignant cells present or whether there is a benign process underlying the findings. If only micro-calcifications are seen on a mammogram, histologic specimens, CNB or a surgical biopsy, are needed (Tabar 1996). In a study on FNA techniques, Kreula concluded that aspiration biopsy can rarely be used on tumours smaller than 5 mm in diameter (Kreula 1990).

The decision of surgical treatment is based on the preoperative findings. When radical treatment is decided on, the clinical picture, the mammogram and the preoperative cytology/histology must be in concordance with each other. This is called a triple diagnosis. When the three are in concordance, it is possible to choose between the surgical methods in individual cases (Hermansen et al. 1984; Morris et al. 1998; Salami et al. 1999). The concordance is best validated when the diagnosticians meet with each other. If there are discrepancies or uncertainties in the preoperative diagnostics, intra-operative frozen sections and/or imprint cytology of the tumour are recommended before ablation and/or axillary evacuation is done (Bianchi et al. 1995; Boerner and Sneige 1998; Ferreiro et al. 1995).

#### **4.3.2 Radiography of tissue removed**

As surgical treatment aims at radical removal of the cancer (White et al. 1995), the tumours are excised with normal tissue around them. To ensure that the diagnosis is made from the correct location of the tissue removed, unpalpable, mammographically found lesions have to be tagged for the surgeon and the pathologist to find them. This is best done by mammography before the operation, and again of the removed tissue. The radiologist can also tell whether the tumour

has been radically removed by comparing the preoperative mammograms with the specimen pictures (Lee and Carter 1995).

#### **4.3.3 Frozen section**

Frozen sections are prepared when a surgeon is uncertain about the nature of a tumour, but wants to perform the surgical procedures in one session. The frozen sections are done while the patient is still in narcosis. Tissue samples are snap frozen, and sectioned in cryostats. Sections of the frozen tissue are rapidly stained, and the pathologists have to make immediate decisions about the nature of the changes. Small tumours at the margins of radial scars, small infiltrating processes in large DCIS processes and very well differentiated tumours may not be reliably diagnosed based on frozen sections (Ferreiro et al. 1995; Speights 1994).

Frozen sections are also used for investigating the margins of large tumours, and DCIS changes (White et al. 1995). The surgeon is best able to select the critical points of tumour growth to the margins, because fibrous septa between the tumour and the central parts of the breast can be palpated when the tissues are cut (Malik et al. 1999).

At centres giving cancer care and where experienced cytological knowledge is thus available, frozen sections may be partially substituted by imprint cytology, especially for the investigation of resection margins and the evaluation of sentinel lymph nodes (Cox et al. 2000)

#### **4.3.4 Final pathology reports**

The final histopathology reports should contain information about all the factors

considered to have an impact on patient outcome, e.g. the established prognostic markers and an evaluation of the radicality of the operation (Vicini et al. 1999; Vicini et al. 2000). The reports are drawn up on the basis of measurements of the freshly resected tissue and from formalin-fixed, paraffin-embedded material of the operation specimens. Handling of the specimens should be standardised for the results to be reliable (Luu et al. 1999; Sauer et al. 1992).

#### ***4.4 Prognosis of breast cancer***

##### **4.4.1 Classical prognostic markers**

###### **4.4.1.1 Stage of the disease**

The stage of the disease has been shown to have an impact on patient outcome (Palmer et al. 1982). The stage is defined by the pTNM classification which includes tumour size, measured from histological sections (pT), extent of axillary nodal involvement, number of involved lymph nodes investigated histologically (pN), and the extent of distant metastases, verified histologically or cytologically (pM) (Hermaneck et al. 1997; Spiessl et al. 1992a). There is ongoing discussion on the incorporation of other prognostic factors into the staging system, but so far no generally accepted recommendations have been made (Yarbro et al. 1999). The prognostic impact of micro-metastases or occult metastases is being debated (McGuckin et al. 1996). There is no agreement on the critical size of tumour cell clusters that should be regarded as metastases (Cox et al. 2000).

###### **4.4.1.2 Tumour grade**

Already in the 1950s, Scarff, Bloom and Richardson introduced histologic grade as a prognostic factor for breast cancer (Bloom and Richardson 1957), and this

grading has been validated (Elston 1984; Le Doussal et al. 1989; Toikkanen and Joensuu 1990). Tumour grade consists of the ability of cancer cells to form glandular structures, their nuclear morphology and mitotic counts (Bloom and Richardson 1957). Elston and Ellis have refined and further stressed the importance of using histologic grading. They have called their classification system, with the inclusion of tumour size and of axillary nodal status, the Nottingham Prognostic Index (NPI) (Galea et al. 1992).

In primary, operable breast cancer, NPI based on tumour size, lymph node involvement and histological grade can identify three prognostic groups (PG) with 10-year survival rates of 83%, 52%, and 13% (Balslev et al. 1994). There are three strong predictors of a good prognosis: 1) Small primary tumour size (Arriagada et al. 1992; Reiss 1989; Skoog et al. 1987; Toikkanen and Joensuu 1990). 2)

Absence of lymph node metastasis (Mann et al. 1999; Rosen et al. 1981; Shek and Godolphin 1988; Sunderland and McGuire 1990; Toikkanen and Joensuu 1990) 3) Low histological grade (Bloom and Richardson 1957; Pereira et al. 1995; Rank et al. 1987; Schumacher et al. 1993; Toikkanen and Joensuu 1990). There are only few studies opposing the strong adverse prognostic significance of lymph node metastasis (Ciatto et al. 1992; Menard et al. 1994).

Tumour grade, nuclear morphology (Ciatto et al. 1992; le Doussal et al. 1989) and mitotic counts are often considered as separate, independent prognostic markers (Aaltomaa et al. 1992a), especially when analysed by morphometric methods (Bacus et al. 1999; Wolberg et al. 1999).

The classical prognostic markers are well established and validated. They form the cornerstone of breast cancer diagnostics, and all other prognosis indicators should be tested against them. But not even these prognostic markers have proven

sufficiently reliable (Arriagada et al. 1992; Sears et al. 1982), and more powerful predictors are still searched for (Blamey et al. 1979; Clark 1992b; Clark 1994; Clark and McGuire 1983; Clark and McGuire 1989; Davis 1996).

#### **4.4.1.3 Cancer type**

Breast cancer is typed according to its morphology and named after the presumed cellular origin in the terminal duct-lobular unit (TDLU) (Azzopardi et al. 1981).

The type of cancer has been shown to have an impact on survival. Breast cancer is largely divided into ductal carcinomas comprising 70-90% of breast cancers; they show morphological differentiation towards ductal epithelium (Elston and Ellis 1998). Lobular carcinomas, comprising 10-30% of breast cancers, resemble the exocrine epithelium in the terminal lobules (Silverstein et al. 1994).

There are several histological types of ductal carcinoma, including small cell ductal and large cell ductal carcinoma (Elston and Ellis 1998; Simpson and Page 1996). The ductal carcinoma of the small cell variety and lobular carcinoma sometimes admix; a special variant of this mixture of low-grade malignancy is called tubulo-lobular carcinoma (Elston and Ellis 1998). Small cell ductal carcinoma may occur in special subtypes, including tubular, cribriform, mucinous (Toikkanen and Kujari 1989) and certain papillary carcinomas. Also large cell ductal breast carcinoma grows in several patterns, metaplastic, medullary and infiltrating micropapillary carcinoma. An infiltrating ductal carcinoma usually provokes the formation of a desmoplastic stroma and scarring, which make such carcinomas tumorous and render them discernible in mammography quite early in their progression. A ductal carcinoma frequently evokes an inflammatory reaction, which is rarely seen in lobular carcinoma (Silverstein et al. 1994).



Lobular breast carcinomas are characterised by small cells with a scanty cytoplasm. In the cytoplasm there are often perinuclear vacuoles, with small periodic-acid-shiff positive dense granules containing glycodeilin (Kamarainen et al. 1997). The nuclei are pale staining, round, with wrinkling of the nuclear membrane (Silverstein et al. 1994). The patients with lobular carcinoma have a greater risk of developing cancer in the contra lateral breast than patients with a ductal carcinoma (du Toit et al. 1991; Lesser et al. 1982). The majority of bilateral cancers are however, of the ductal type (Engin 1994). The lobular carcinomas often grow in a diffuse manner, invading most of the breast without forming palpable tumours or destroying underlying structures. Due to its growth pattern it may also be undetectable mammographically (Silverstein et al. 1994). From the pathologist's viewpoint lobular carcinoma is a great challenge in preoperative diagnostics. It may be difficult to identify in FNA due to the small pale nuclei, and may not be recognised in CNB and surgical margin specimens during surgery due to its diffuse growth pattern. This may explain why lobular carcinomas more frequently have local recurrences after breast-conserving therapy (du Toit et al. 1991). The long-term prognosis of patients with lobular carcinoma is nevertheless still better than that of the average breast cancer patient (du Toit et al. 1991).

#### **4.4.2 Other histological criteria of breast cancer**

##### **4.4.2.1 Vessel invasion and inflammation**

Several studies have presented compelling evidence to support the prognostic importance of the recognition of tumour cells invading lymphatic and blood vessels (Pinder et al. 1994; Toikkanen and Joensuu 1990). This parameter appears to be particularly valuable in the hands of experienced histo-pathologists who have

developed standardised criteria and expertise in vessel recognition. However, its application is seriously hampered by inter-observer and intra-observer differences in interpretation. A more uniform and objective approach, such as the use of immunohistochemical techniques to recognise endothelial linings, may be helpful in overcoming these obstacles. This may render lymphatic and blood vessel invasion a reliably reproducible indicator that a pathologist can utilise to recognise high-risk patients and recommend appropriate therapy (Lee et al. 1986; Marson et al. 1999).

#### **4.4.2.2 Tumour border**

Pushing borders of tumours, instead of ragged infiltrating growth, are also considered a sign of poor prognosis (Toikkanen and Joensuu 1990). On the other hand, accumulation of lymphocytes at the tumour borders has been regarded a sign of good prognosis (Toikkanen and Joensuu 1990).

#### **4.4.2.3 Radial scars**

The radial scar concept was born in the eighties (Linell et al. 1986). Radial scars are very common. They appear to be remnants of scarring procedures that pull tissue inwards, giving the appearance of a star, similar to that of a small ductal cancer. At the centre of this still benign scar are elastic bundles that strangle ducts and lobules (Linell et al. 1986). At the periphery, there are dilated ducts often with different stages of proliferation in the epithelium. There may also be hyperplasia and LCIS of the lobules. Linell thought originally that the strangled ductuli in the centre were in fact already malignant (Linell et al. 1986). Nowadays radial scars

are considered to be normal scars, representing reparative processes that might render the tissues more vulnerable to cancerous proliferation (Elston and Ellis 1998). In mammograms, radial scars appear as “black stars” with an empty centre, as opposed to the “white stars” of overt cancers. The “black stars” have longer branches, and they are more slender than the “white stars” in mammograms (Tabar 1996).

#### **4.4.2.4 ADH, DCIS and LCIS versus infiltrating cancer**

A variety of proliferative lesions in the breasts have been recognised. Most of such proliferative changes are associated with a higher incidence of breast cancer than normal breast epithelium (Fisher et al. 1999; McDevitt et al. 1992; Raju and Vertes 1996). The events that eventually turn such lesions into malignant growth are still poorly understood. Patients with ADH have a twofold risk of developing an invasive cancer in 5 years as compared to women with normal breast epithelium (Dupont and Page 1989; McDevitt et al. 1992). Patients with LCIS and with DCIS of the small cell variant have a similarly increased risk of developing an infiltrative disease (Fisher et al. 1996; Wörnberg et al. 2000). This risk is estimated to be 4-5 times that of average women (Wörnberg et al. 2000). Patients with DCIS of the large cell variant will regularly get a cancer at some point in their lives. The critical molecular events leading to malignancy are still to be identified. Genetic changes, typical of an overt breast cancer, can also be found in some of the DCIS and LCIS lesions (Visscher et al. 1996).

## ***4.5 Patient-related prognostic markers***

### **4.5.1 Age of the patient**

Age influences the tissues and physiological processes in the body (Clark 1992a). Hormone-producing tissues and female reproductive organs are affected in particular. Even though the physiological proliferation of epithelia slows down with age, the cumulated damage to the genome of epithelial cells increases with time. This has an impact on breast cancer in a twofold manner. Although cancer is more frequent in postmenopausal patients (Clark 1992a; Dhodapkar et al. 1996), the cancers of premenopausal patients are usually more rapidly progressive (Albain et al. 1994; Marcus et al. 1994). Clinical, but not anatomical, tumour size is larger in young patients, suggesting higher stromal activity. The policy of hormone replacement therapy given to ageing women may increase the risk of neoplastic changes in oestrogen-responsive epithelium (Snedeker and Diaugustine 1996). However, the cancers developing during hormone replacement therapy are often of low-grade malignancy (Bonnier et al. 1995b).

In univariate analyses of breast cancer, the following variables have been found to correlate significantly with shortened recurrence-free survival in premenopausal women: Young age, large tumour size, high number of metastatic lymph nodes in the axilla, high histological grade, and negative ER and PR status of the tumour. In multivariate analyses, young age is the most important adverse factor in premenopausal patients, followed by tumour size and histological grade, whereas PR status is of borderline significance. All of these variables should be included in multivariate analyses testing the value of more recently introduced prognostic

factors (Davis 1996; de la Rochefordiere et al. 1993; Dhingra and Hortobagyi 1996; Mouridsen et al. 1992). Younger women have a higher risk of local recurrence but, unlike older women, recurrence of the tumour does not worsen the already unfavourable outcome (Bonnier et al. 1995a).

The effect of age as a prognostic factor in recurrent breast cancer was studied in 1,168 patients treated according to the Eastern Co-operative Oncology Group (ECOG) protocols. Survival was significantly shorter in patients under 35 years of age ( $P = .03$ ). This was true even when other good prognostic factors were present. Eighteen prognostic factors were analysed, and their power of predicting survival was studied in each of the six age groups. Patients with a better performance status, less than three sites of metastases, and without visceral or nodal metastases had a longer survival time. A Cox proportional hazards model of survival showed that younger age groups, irrespective of menopausal status, had shorter survival times. The predicted median survival times after the first recurrence were 491 days for patients under 35 years of age, 590 days for patients 36 to 45 years of age, and 700 days for those over 45 years of age (Falkson et al. 1986).

#### **4.5.2 Diet and life-style**

In Japan, breast cancer is a rare disease as compared to the Western Countries (Tominaga and Kuroishi 1999). When Japanese women emigrate to the USA they acquire the same risk for breast cancer as the main population of women in the USA in a few generations' time (Probst-Hensch et al. 2000). This is considered to be due to environmental and dietary factors (Maskarinec 2000; Probst-Hensch et al. 2000).

A high body mass index increases the risk for breast cancer (Lam et al. 2000), and

is a marker for poor prognosis according to some investigators (Greenberg et al. 1985), which is, however, denied by others (Obermair et al. 1995).

Nulliparous women are over-represented among patients with large tumours when diagnosed. Women with a late first childbirth have tumours that are more disseminated at the time of diagnosis than women with an early first childbirth. However, such associations are not seen for women diagnosed with small tumours or women with cancer that has not spread widely (Wohlfahrt et al. 1999).

The same factors that decrease the risk of developing breast cancer have been shown to worsen the prognosis of developed breast cancer (Korzeniowski and Dyba 1994). An adverse psychological reaction, like depression, related to the disease has been reported to be a negative factor for patient outcome (Watson et al. 1999).

#### ***4.6 Molecular prognosis markers of breast cancer***

##### **4.6.1 Genetics of breast cancer**

Malignant cells are characterised by an unstable genome, making their behaviour unpredictable (Gisselsson et al. 2000). Nicolson suggested already in the beginning of the eighties that cell surface proteins play a decisive role in the process of metastasis (Nicolson 1982). In the classical mouse melanoma metastasizing experiments Fidler and Nicholson showed that cells with different surface properties had a different propensity for metastasizing into selected organs (Fidler 1973). They also found that primary tumours contained subclones of cells having different cell surface properties. They thus proposed that this might be at least partially caused by post-transcriptional heterogeneity, due to different

glycosylation of the same surface molecules. This again might be the result of changed expression of the glycosylation enzymes (glycosyl transferases).

#### **4.6.1.1 DNA analysis by flow cytometry**

Flow cytometric DNA analysis of breast cancer yields information on the DNA content of single cells, i.e. the ploidy and also of the fraction of cells in active DNA synthesis, i.e. the proliferative activity (Feichter et al. 1988; Ferno et al. 1992; Gaglia et al. 1993; Witzig et al. 1994). Knowledge of the DNA synthesis phase fraction gives seemingly more important prognostic information than knowledge of the ploidy (Beerman et al. 1990; Fallenius et al. 1988; Ferno et al. 1992; Kallioniemi et al. 1987; Tubiana et al. 1984). Ploidy measured by FC gives only crude information on lost or gained genetic material. The prognostic power of DNA flow cytometry measurements has been enhanced by combining proliferation activity and ploidy (Kallioniemi et al. 1988).

#### **4.6.1.2 Oncogenes and tumour suppressor genes**

Loss of heterozygosity from chromosomes 1, 3p, 4, 6q, 7q, 8p, 11, 13q, 16q, 17, 18q, and 22q is frequently seen in breast cancer tissues. LOH and chromosomal deletions may lead to inactivation or loss of tumour suppressor genes (Bieche et al. 1999; Knuutila et al. 1999). Proto-oncogenes are normal human genes possessing the potential to become oncogenic (Chan and McGee 1987). These genes are mostly household genes that are involved in growth, differentiation or survival of normal cells. When such genes become overactive, through e.g. DNA damage, they may participate in the carcinogenesis (Elledge and Allred 1994). Genetic

abnormalities that are frequently observed in breast tumours are amplification of the proto-oncogenes (myc and c-neu/erbB-2/her-2). Some protein products of tumour suppressor genes in the normal cell arrest the cell cycle, e.g. p53. When such a normal protein is absent or inactive, the proliferation of cells can be unlimited.

There have been more or less fruitful attempts to correlate disturbances in oncogene functions to the outcome of disease. Reports on the inverse effect of the accumulation of HER2 (Lipponen et al. 1993a), bcl-2 (Lipponen et al. 1995), and of p53 (Lipponen et al. 1993b) in cells on patient prognosis are numerous. But the predictive power of the accumulation of these proteins has not been as strong as grade or proliferation.

In the beginning of nineties, the search for specific genetic lesions in breast cancer started anew from studies on hereditary cancers. Several genetic alterations were found. Epidemiological studies had revealed a linkage between early-onset breast cancer and ovarian cancer. A genetic marker was linked to chromosome 17q21 (Chamberlain et al. 1993; Eng and Ponder 1993; Friedman et al. 1995). The genes involved, BRCA1 and 2, were originally found in Ashkenazi Jewish descendants (Goldgar et al. 1993; Goldgar et al. 1994).

BRCA1 maps proximal to D17S579 on chromosome 17q21 as shown by genetic analysis (Chamberlain et al. 1993). Recently it was shown that normal BRCA1 is a zinc finger protein which binds to introns of important cellular regulatory genes (Li et al. 2000). Deletion of the BRCA1 gene in knockout mice is not compatible with life (Cressman et al. 1999). In fibroblast cultures, lack of BRCA1 gave rapid proliferation, which was further accentuated by a simultaneous lack of p53. Such cells were, however, increasingly sensitive to DNA damaging agents, suggesting a



role for both gene products in DNA repair functions. After continued culture of BRCA1 and p53 deficient cells, cell populations with still increased growth rates could be isolated, which could mimic the events that occur during malignant transformation in BRCA1 deficient epithelia (Cressman et al. 1999).

BRCA2 on chromosome 13q12-13, was cloned in 1995 (Goldgar et al. 1995). The cells produce maximum levels of BRCA2 mRNA in late G1 and in S-phase. Expression of BRCA2 has been shown to be independent of DNA synthesis. The kinetics of up-regulation of BRCA2 mRNA appears to be similar to that of BRCA1, suggesting that the two genes could be commonly controlled. The results also imply that these two tumour suppressor genes are active during the growth of normal epithelia, and may guard duplicating DNA (Vaughn et al. 1996a; Vaughn et al. 1996b)

Mutations in BRCA2 are thought to account for as much as 35% of all inherited breast cancer [Couch, 1996 #90]. The heterogeneity of the mutations found, together with the large size of the gene, make clinical testing for BRCA1 and BRCA2 mutations technically challenging (Abeliovich et al. 1997). In sporadic breast cancer, LOH of BRCA1 or of BRCA2 does not add decisive prognostic value, as stated for familial breast cancer (Bieche et al. 1999). Some investigators have doubted the prognostic value of these genetic changes even in familial breast cancers (Phillips et al. 1999).

Certain kinds of breast tumours have certain genetic aberrations. Well differentiated ductal carcinomas often show loss of 16q, and a few other genetic changes, whereas high grade ductal carcinomas have lots of genetic abnormalities (Buerger et al. 1999; Garcia et al. 1999; Gonzalez et al. 1999), among them, often an expression of mutated BRCA2 (Bieche et al. 1999).

The gains and losses of genetic material in tumours have lately been extensively investigated using CGH and FISH (Kallioniemi et al. 1994; Knuutila et al. 1999; Tirkkonen et al. 1998). By DNA and tissue microarrays of tumours, information is obtained on more discrete changes in gene structures and/or expression (Barlund et al. 1997; Kononen et al. 1998).

#### **4.6.2 Immunohistochemical characterisation of tumours**

IHC methods are widely used in diagnostic pathology. The methodology is relatively simple, and under stringent conditions fairly reliable (Battifora 1999). As most archival material is formalin-fixed and embedded in paraffin, there is frequently a need to retrieve antigenic epitopes. The procedure, with antigen retrieval and signal enhancement-secondary antibodies, does not allow reliable quantitation, but in most instances it is sufficient to show the expression of a certain epitope. If quantification is essential, cell line specimens with known amounts of the investigated protein may be added to the process for comparison (Battifora 1999). The antibodies used must nevertheless be rigorously tested and validated, and control slides must be included in every staining procedure (Busmanis et al. 1994). Most genetic techniques are more complicated, time-consuming, and also more prone to errors, and are therefore not as useful in clinical pathology as demonstration of gene products by immunohistochemistry (Martegani et al. 1999).

#### **4.6.3 Lectin staining for tumour characterisation**

Glycosylation means the modification of cell surface proteins after transcription,

thus multiplying the structural diversity of the proteins and also their functions (Martegani et al. 1999). Lectins act, as nature's own antibodies, which recognise and bind to specific glycoconjugates. Most lectins are purified from plants. Reactivity with some lectins like PNA have been shown to have some predictive value by indicating ability for metastasis together with HER2 (Thomas et al. 1993). Other investigators claim that altered glycosylation has prognostic power in itself. Fenlon showed that UEA1 reactivity of the tumour cell was related to the disease-free interval and survival, and HPA reactivity was related to lymph node stage, time to regional recurrence and to survival in breast cancer patients (Fenlon et al. 1987). Paydas has suggested Con A reactivity to correlate with a low tumour grade (Paydas et al. 1994).

#### **4.6.4 Hormone receptors as markers for differentiation and hormone dependency**

Given that the breast is a sex-steroid-dependent organ, the development and growth of cancer in the breast is often dependent on sex steroids. The more differentiated the cancer is, the more likely it is to depend on these hormones. Hormone receptors, oestrogen receptors (ER) and progesterone receptors (PR) mediate dependency on oestrogen and progesterone. ER- and PR-negative tumours are rarely (<10% probability) dependent on sex hormones for growth (Pascual et al. 1983; Reiner et al. 1987; Saez et al. 1984).

Measuring the tumour content of ER and PR was first done either by radio-ligand binding assay (ER-LBA) or enzyme immunoassay (ER-EIA) (Godolphin et al. 1981; Gotteland et al. 1994). Nowadays direct IHC demonstration of ER and/or PR in tumour cells by mAbs have proven more reliable in predicting prognosis and the response to anti-hormone therapy (Chariyalertsak et al. 1999; Cowen et al.

1990; Ellis et al. 1985). The presence of PR has turned out to be more reliable than the presence of ER as a prognosticator and as an indicator of response to hormone therapy (Mathiesen et al. 1991; Merkel and Osborne 1989). Also the impact of IHC positivity for ER and PR is combined with other factors affecting patient outcome, such as menopausal status and patient age (Mason et al. 1990; Moot et al. 1987; Neville et al. 1992; Papatestas et al. 1986).

Antibodies against ER were first available in 1985 (Ellis et al. 1985). Initially they reacted only with fresh and frozen tissue. MAbs to PR were commercially available in 1994, and useful mAbs that react also with formalin-fixed tissue are now available (Chariyalertsak et al. 1999; Stierer et al. 1993). Hormone receptors are labile proteins that start to degrade immediately after removal of tissue from the patient. Prompt fixation or immediate snap freezing of the tissue is therefore essential. Extended fixation may also destroy the receptor epitopes (Battifora 1999). Archival material is therefore not always reliable for immuno-staining of hormone receptors. Still, archival material has shown a correlation between positive receptor staining of cancers and good prognosis (Stierer et al. 1993). This correlation is not independent of tumour grade or other classical prognostic markers. ER reactivity shows no independent prognostic value, with the possible exception of low grade node-negative, small cancers (Joensuu and Toikkanen 1992; McGuire et al. 1986). Some investigators have found that ER and PR positivity is an independent predictor of good prognosis (Knight et al. 1977; Moot et al. 1987). ER- and PR-positive tumours tend to be smaller and of lower grade than hormone-receptor-negative tumours (Luna-More et al. 1996).

Some 40-60% of ER-positive tumours do not respond to hormonal therapy (Osborne et al. 1980). This has been considered to reflect the occurrence of

alternatively spliced receptor proteins, some of which may be over-active, whereas others may have lost their biologic activity. Even normal glandular epithelium in the breast contains low amounts of variably spliced receptor proteins (Anandappa et al. 2000).

In 1997 a second ER was cloned and mapped to chromosome 12. This ER was named ER beta, and the original ER has been renamed ER alfa. These two ERs bear substantial homology with each other (Macgregor and Jordan 1998). In breast cancers both ERs are often coexpressed (Jarvinen et al. 2000b). The relative impact of the two isotypes of ER on the prognostication and the therapy of breast cancer remains to be established.

#### **4.6.5 Kinetics of breast cancer**

##### **4.6.5.1 Proliferation rate**

The rate of proliferation has been considered a more powerful prognostic factor than tumour size. The estimation of proliferation rate has been done by counting the frequencies of mitoses in the histological sections (Aaltomaa et al. 1991), by <sup>3</sup>H-thymidine incorporation tests (Tubiana et al. 1984) or by means of proliferation indexes measured by DNA cytometry (Witzig et al. 1994; Witzig et al. 1993). The simplest way of measuring proliferation is IHC detection of different proteins associated with proliferation. There are several proteins associated with cell proliferation. The first antibodies that emerged were the anti-cyclins and antibodies against PCNA. The results of immunostaining with these antisera correlated with SPF and patient outcome (Aaltomaa et al. 1993; Visscher et al. 1992). MAbs that react with different epitopes of PCNA, Ki-67 and MIB are now

available (Cwikla et al. 1999; Depowski et al. 1999). The expression of proliferation-associated antigens during the SPF varies, and so does the number of positive cells in the tumours (Thor et al. 1999). The growth fraction plays a key role in determining the prognosis of breast cancer patients (Courdi et al. 1989; Lorenzato et al. 2000b; Pietilainen et al. 1996).

#### **4.6.5.2 Apoptosis**

Apoptosis is defined as programmed cell death. Apoptosis is energy-consuming, and does not give rise to inflammation and scarring. Apoptosis appears as lumpy condensation of the chromatin, and apoptotic chromatin particles are engulfed in macrophages (Vakkala et al. 1999).

Several of the genes involved in the regulation of apoptosis are proto-oncogenes or tumour suppresser genes. The study of Wang provides evidence that also the physiological responses of breast epithelial cells to sex hormones involve control of the apoptotic pathway (Wang and Phang 1995). This is also shown for antioestrogens like Toremifene (Warri et al. 1993). Deregulation of apoptosis may contribute to the pathogenesis of breast cancer, via an imbalance between anti-apoptotic genes (such as bcl-2/bcl-x) and apoptosis-promoting genes like bax (Bargou et al. 1995). Apoptosis and proliferation together define tumour kinetics, and both are linked to the prognosis of the patient (de Jong et al. 2000; Nishimura et al. 1999; Vakkala et al. 1999).

#### **4.6.6 Oncogen products in breast cancer**

##### **4.6.6.1 Fas (CD95), the death receptor**

The Fas receptor protein is normally expressed on most epithelial cells. It triggers apoptosis when in contact with the Fas-ligand, expressed by activated T-cells. The Fas-ligand is a protein homologous with tumour necrosis factor alfa. Down-regulation of the Fas receptor has been seen in certain drug-resistant breast cancer cell lines (Cai et al. 1996). Fas is a cell-surface receptor that exists in two forms, transmembrane and soluble. The former induces apoptosis by ligation of FasL or agonistic anti-Fas antibody, whereas the latter inhibits Fas-mediated apoptosis by neutralising its ligand (Ueno et al. 1999).

##### **4.6.6.2 p53**

The gene for p53 consists of 11 exons encoding for a nuclear phosphoprotein. All of the biological function(s) of p53 are still not evident, but substantial data indicates that p53 is a transcription factor that regulates cell proliferation and apoptosis (Harris 1996). Loss of p53 function eliminates growth arrest in response to DNA-damage and facilitates the accumulation of mutations. The main role of the p53 gene appears to include control of cell cycle checkpoint(s) and maintenance of the integrity of the genome.

Changes in the p53 gene are the most frequently encountered genomic change in human malignancies. Normal p53 protein is rapidly degraded. Most p53 mutations result in a non-functional protein that accumulates in tumour cell nuclei, and is detectable by IHC (Allred et al. 1993; Lucas et al. 2000). Initial IHC studies of p53 in breast cancer focused on the association between cancer prognosis and p53

over-expression (Barbareschi 1996). Only about one-third of such studies reported an association in the beginning, but differences in techniques and variability in the frequency and intensity of immuno-reactivity obscured these early analyses (Blazyk et al. 2000).

Cells lacking normal p53 function have a selective growth advantage and are more resistant to ionising radiation and anti-cancer drugs (Aas et al. 1996). Cancers with mutated p53 genes may therefore behave more aggressively than tumours with a preserved normal function of p53.

The presence of p53 as detected by IHC has later been reported to predict the response to certain apoptosis-inducing cytotoxic drugs (Aas et al. 1996). Despite the strong correlation between accumulation of p53 protein and the rate of tumour cell proliferation, both factors are independently associated with a poor prognosis. This suggests that p53 may have other biological functions in addition to cell-cycle regulation (Allred et al. 1993). Tissue immuno-reactivity for p53 is significantly associated with the tumour grade and a negative ER status (Willsher et al. 1996).

#### **4.6.6.3 HER2**

The neu/erbB-2/her-2 oncogene was first discovered by Weinberg and collaborators in 1981 (Shih et al. 1981; Shih et al. 1979) in chemically induced rat neuroblastomas. The human counterpart was independently cloned using cDNA probes from parts of the epidermal growth factor receptor, with which HER2 shows homology. HER2 is a 185 kDa membrane-bound protein that belongs to the tyrosine kinase family (Coussens et al. 1985). The gene is located on human chromosome 17q21-22 (Coussens et al. 1985). No ligand to HER2 has been found,



but it forms heterodimers with other members of the HER-tyrosinkinase family to potentiate the tyrosine kinase activity of, for example, c-erbB-3 and its ligand (Graus-Porta et al. 1997).

HER2 is overexpressed in about 30% of breast cancers (Slamon et al. 1987), mainly of the large cell ductal type.

Expression of HER2 is often more intensive in the DCIS component of cancers, suggesting that the protein may play a role in the process of carcinogenesis. But it seems that HER2 is no longer needed for the tumour invasion (Allred et al. 1992). mAbs against the HER2 protein inhibit the proliferation of cancer cells over-expressing the receptor (Hudziak et al. 1988). Multivariate analyses using proportional hazard regression models have demonstrated that HER2 positivity continued to predict a poor outcome even when accounting for the effects of other prognostic factors (Anbazhagan et al. 1991). Even when only cases with favourable (Stages I and II) nuclear grades were analysed, the overall survival and disease-free survival were significantly shorter in HER2-positive cases, with a 9-fold increase in risk of death and a 3-fold increase in risk of relapse. There is much evidence suggesting that the demonstration of HER2 expression by IHC may help to define breast cancer patients at greater risk of dying of the disease among patients with low-stage/low-nuclear-grade tumours, as such patients have hitherto been considered to have a good prognosis (Battifora et al. 1991).

Amplification of the gene for HER2 has also been shown to be an unfavourable marker in inherited breast cancer (Xing et al. 1996).

Humanised antibodies against HER2 have not quite fulfilled the expectations put in them (Piccart 2001; Schaller et al. 1999). But the co-amplification of

topoisomerase alfa with the gene for HER2 has changed the first-choice treatment modalities of breast cancer (Hellemans et al. 1995; Jarvinen et al. 2000a; Sandri et al. 1996)

#### **4.6.6.4 Bcl-2**

An important group of proteins influencing apoptosis is the bcl-2 family of proteins, some of which, like Bax (Bargou et al. 1995; Krajewski et al. 1995), promote, and others like bcl-2 inhibit apoptosis (Schorr et al. 1999). Bcl-2 is normally expressed on the inner mitochondrial membranes in the cell. Bcl-2 counteracts the pro-apoptotic activity of p53 during tissue growth or repair. The bcl-2 gene is located at 18q21 (Nathan et al. 1994). Translocation of the gene (t14:18) to an active locus leads to the development of follicular lymphoma (Tsujimoto et al. 1985). Via an alternative splicing, this gene can encode two proteins of 26 and 22 kDa respectively. The larger protein is more abundant in all tissues. A robust expression of bcl-2 protects cells from apoptosis (Lu et al. 1995). Other biological functions of bcl-2 protein are not well known, but a role for bcl-2 in epithelial differentiation towards mesenchyme is suggested (Lu et al. 1995), like the participation of bcl-2 in the process of tumorigenesis (Nathan et al. 1994).

Several studies have shown that a low expression of bcl-2 in breast cancer tissue is associated with a poor outcome (Joensuu et al. 1994) and vice versa: High expression of bcl-2 is associated with a good outcome for the patient (Lipponen et al. 1995; Vakkala et al. 1999). A high level of bcl-2 expression is mostly found in well-differentiated tumours and associates with a favourable prognosis. bcl-2 expression has not, however, proved to be an independent prognostic factor in breast cancer (van Slooten et al. 1996), only in node-positive and recurring disease

(Vakkala et al. 1999).

#### **4.6.6.5 p21<sup>ras</sup> (H-ras)**

H-ras genes are rendered oncogenic either by mutation or by overexpression. Using a mouse mammary tumour model, consisting of genetically related sister sub-lines with variant metastatic capacities, a direct correlation between metastatic behaviour and expression levels of normal H-ras was found (Pethe and Shekhar 1999). Although H-ras mutations are infrequent in breast cancer, occurring only in about 5%, there is considerable evidence to suggest that H-ras signalling pathways are deregulated in breast cancer cells. Elevated levels of normal H-ras have been shown to play a crucial role in tumorigenesis. 50% of human breast cancers express elevated levels of H-ras. Thus, it is possible that the aberrant function of Ras or Ras-related proteins may contribute to breast cancer development and/or progression. Over-expression of the H-ras gene has been postulated to result from transcriptional deregulation. Also oestrogen-mediated regulation of H-ras transcription takes place in mammary tumour cells (Pethe and Shekhar 1999).

The presence of H-ras, p21<sup>ras</sup> oncoprotein was claimed to be as powerful marker for poor prognosis as axillary lymph node metastases (Watson et al. 1991).

Watson found no significant relationship between the levels of p21<sup>ras</sup> and the menopausal status of the patient, tumour ER, grade or clinical stage. There was, however, a significant trend for tumours to be associated with lymph node involvement when p21<sup>ras</sup> was increasingly expressed. Elevated levels of p21<sup>ras</sup> were also significantly related to early disease recurrence and death from the tumour in early breast cancer (Watson et al. 1991)

#### **4.6.7 Adhesion**

The invasive and metastatic process is a series of events in which adhesion and loss of adhesion are sequentially switched on and off. Loss of adhesion in normal epithelial cells leads to cell death, often by apoptosis. Loss or alteration of adhesion in malignant cells may lead to metastasis.

##### **4.6.7.1 CD44**

CD44 is a membrane-bound glycoprotein encoded by a gene composed of at least 20 exons with many alternatively spliced transcripts (Iida and Bourguignon 1995). Different splicing variants are expressed on different epithelial cells (Iida and Bourguignon 1995; Takeuchi et al. 1995). The gene for CD44 consists of multiple domains. The glycosylation of the protein varies according to its surroundings or enzymatic balance, rendering it a difficult target for IHC. Especially the variant isoforms are frequently not recognised by their specific mAbs due to different glycosylation. CD44 is thought to contribute to the interaction between cancer cells and the matrix (Martegani et al. 1999). Expression of CD44 by cDNA transfection to AU-565 breast cancer cells induced an up-regulated expression of the intercellular adhesion molecule 1 (ICAM-1). The induction of ICAM-1 by CD44 may affect the morphology, differentiation state, and metastatic propensity of mammary tumour cells expressing HER2 (Bacus et al. 1993).

##### **4.6.7.2 Integrins**

The integrins belong to a family of transmembrane receptors that connect the cell to the extracellular matrix and anchor it to the cytoskeleton. There are more than

20 integrin receptors formed by heterodimerization between different alfa and beta subunits. Normal human breast epithelial cells express at least four alfa integrins (1,2,3 and 6) and two beta integrins (beta 1 and beta 4) which dimerize to form alfa-beta receptors. The integrin bridge is a bi-directional conduit for the transfer of information between the surroundings and the cell. Both qualitative and quantitative changes in integrin expression have been associated with breast cancer (Hansen and Bissell 2000).


#### **4.6.7.3 Cadherins and catenins**

Cadherins form an intercellular zipper between homotypic cells. They are transmembrane calcium-binding proteins with varying numbers of conserved repeated amino acid sequences (Takeichi 1990).

E-cadherin (L-CAM, uvomorulin), with a mature protein product of 120 kDa, is the epithelial cadherin. The gene for E-cadherin is located on chromosome 16q22 (Takeichi 1990). It is often lacking in invasive breast cancer cells (Frixen et al. 1991), especially in lobular cancer (Berx et al. 1995; Rasbridge et al. 1993). There are also malignant cells with normal E-cadherin, but with defective catenins (Pierceall et al. 1995). Catenins are intracellular proteins that form dimers and heteromers between themselves and with cadherins (Nagafuchi et al. 1994).

Figure1. E-cadherin-catenin complex. E-cadherin binds to alpha-, beta- and gamma-catenin and other linkage proteins and is therefore linked to the cytoskeleton. The components of the complex bind to each other in a homophilic interaction and play a key role in cell-cell adhesion. This interaction is dependent on extracellular calcium levels. Catenins bound to E-cadherin may exchange with their intracellular pool.

From: JIANG: Br J Surg, Vol 83,437-46



Many aggressive forms of breast cancer express the neural cadherin equivalent N-cadherin (Nieman et al. 1999). When stimulated with fibroblast growth factor, N-cadherin-containing cells can produce matrix metalloproteinase-9 with the ability to digest components of the extracellular matrix (Hazan et al. 2000). HER2 has also been shown to bind to catenins (Ochiai et al. 1994).

#### **4.6.8 Metastasis**

Metastasis is a complicated biological process. It comprises the detachment of malignant cells from their original place of growth and their transport to a new place of growth. At the new location the tumour cells have to be able to provide themselves with nursing blood flow and a suitable matrix environment.

Metastasis, as a prognostic marker, has been discussed in the context of the stage of the disease (Spiessl et al. 1992b).

Small tumour clusters have been found in the lymph nodes and bone marrow in breast cancer patients already when the primary lesion has been only at the DCIS stage (Cote et al. 1999). The consequence of this finding for the patient is still under debate (Karrison et al. 1999; Spratt 2000), although some investigators have shown that the prognosis of those patients with tumour cell clusters in their bone marrow aspirates is worse than for those in whom they have not been found (Diel et al. 1996; Diel et al. 1992).

#### ***4.7 Treatment of breast cancer***

Surgical removal of the tumour is considered the treatment of choice in breast cancer, even though some French radiotherapists have successfully used radiotherapy alone (Bataini et al. 1978). This treatment, however, resulted in fibrosis of the breast in 10% of the patients (Bataini et al. 1978). Still it appears that postoperative radiotherapy adds significant benefit to the prognosis of most breast cancer patients (Wallgren et al. 1986). Small tumours at the periphery of the mammary gland are preferentially operated on by removal of only one segment of the breast (Luu et al. 1999; Malik et al. 1999). Mastectomy is performed when the tumours are large, adhere to the skin, or are centrally located. When preservation of the breast is very important to the patient, preoperative medication with chemotherapy may be given in order to reduce tumour size before the operation. In such cases pre-treatment assessment of the known prognostic/predictive markers is important, because pre-treated tumours may behave differently than untreated ones in the prognostication tests used (Zambelli et al. 1999).

Evacuation of the lymph nodes from the arm pit is performed routinely today when diagnosis of a malignant infiltrative cancer is made. The presence of tumour spread to the axillary lymph nodes is the most powerful predictive factor known (Jatoi 1999; Zurrida et al. 1999). In 1990 Umberto Veronesi showed that lymph node drainage from a certain part of the mammary gland takes place in a certain order, first to the sentinel lymph node (Veronesi et al. 1993; Veronesi et al. 1990). This enables the staging of breast cancer disease without mutilating the patient (Veronesi et al. 1999). The completion of the ongoing evaluation of the sentinel lymph node (SNL) studies may alter the policy regarding the axillary evacuation



(Cox et al. 2000; McCready et al. 1999). The SLN procedure requires a multi-disciplinary approach and is a learning process for the whole team (Guenther 1999). Some investigators also claim that tumours less than 1 cm in diameter have such a low risk of lymph node metastasis that their lymph nodes can remain uninvestigated altogether (Dimitrakakis et al. 1999).

The choices of post-operative treatment are made on the basis of established prognostic/predictive markers (Winchester 1991). These choices include radiotherapy (Lavin et al. 1994), chemotherapy (Sledge et al. 2000; Wood 1994; Zambelli et al. 1999), immunotherapy (Schaller et al. 1999; Tokuda et al. 1999) and antihormone therapy (Sledge et al. 2000; Teixeira et al. 1995).

## **5 Aims of the study**

This study was undertaken to identify factors which might predict the behaviour of breast cancer, and in particular to find out whether some IHC and/or cell kinetic patterns of the cancer cells could predict the outcome to the patient. The specific aims of the present study were:

1. To investigate whether metastatic cells differ from primary tumour cells regarding their surface membrane glycoconjugates
2. To study the prognostic power of ploidy and SPF parameters defined by flow cytometry in advanced breast cancer
3. To determine which of the prognostic factors in our use could be evaluated from FNA material
4. To find out whether preneoplastic epithelium differs from invasive cancer

regarding oncogene activation, proliferation and apoptosis-related proteins

5. To correlate the tumour expression of HER2 and p53 with survival in advanced breast cancer.

## 6 Materials and methods

Formalin-fixed and paraffin-embedded archival breast cancer material was used in all the studies, except the FNAB study (III). Detailed information about the numbers and kinds of tissue are given in Table 1 and the original publications (I-V). For the FNAB study, freshly aspirated tumour cells were examined and compared with fresh material from the surgical specimens.

Table 1: The patient material used in this work.

Study No.	No. of primary tumours	No. of metastases
I	18	21
II	96	53
III	52	-
IV	118	50
V	97*	-
* of which 35 were benign, 28 in situ carcinoma and 34 malignant		

### ***6.1 Tumour grading and typing***

Tumour typing was performed according to WHO (Azzopardi et al. 1981). The pTNM classification was done according to UICC 1992 (Spiessl et al. 1992b). The cancers were graded according to Elston and Ellis' (Elston 1984; Galea et al. 1992) modification of Bloom and Richardson's original classification from 1957 (Bloom and Richardson 1957).

Benign breast lesions were first classified according to Dupont and Page (Dupont and Page 1985) but as there were so few of them in each group, they were pooled into atypical ductal hyperplasia (ADH) and papillomas. The ADH group included four cases of atypical lobular hyperplasia, one fibroadenoma with unusually proliferative epithelium with atypia, and two sclerosing adenomas with an unusually florid appearance. Cysts and chronic cystic mastopathia without epithelial atypia were excluded. Ductal cancer in situ was graded into low/intermediate-grade, and high-grade types, DCIS1-2 and DCIS3. The DCIS1-2 was further subdivided into those without necrosis (DCIS1) and those with necrosis (DCIS2), as described by Silverstein and co-workers (Silverstein et al. 1995).

### ***6.2 Lectin histochemistry***

FITC-conjugated lectins were used on archival material of primary tumours and their metastases. The lectins used and their specificities are given in Table 2 and study I. They were all obtained desiccated from Sigma chemicals Co. Ltd. After deparaffination and hydration, slides were incubated for 30 min in moist chambers in the dark with the FITC-conjugated lectins diluted to 0.05mg/ml in phosphate-

buffered saline (pH 7.2). The slides were then washed in saline, mounted in veronal-glycerol, and examined and photographed in a fluorescence microscope.

Lectin, origin, common name	Acronym	Carbohydrate specificity	Inhibitor
Bandereia simplicifolia, griffonia	BSII	D-Gal	Lactose
Concanavalla ensiformia, jack bean	Con A	D-GLc, a-D-Man	D-GalNac
Helix pomatia, edible snail	HPA	N-acetyl-galactosamine	N-acetyl-galactosamine
Arachis hypogea, peanut	PNA	Gal-beta-(1-3)-GalNac	Lactose
Ricinus communis, castor bean	RCA1	Beta-D-Gal	Lactose
Ulex europaeus, gorse	UEA	L-fucose	L-fucose
Triticum vulgaris, wheat germ	WGA	(beta-(1-4)D-GlcNAc)2NeuNAc	NeuNAc

Table 2: The fluorochrome-conjugated lectins used in this work and their nominal specificities.

### 6.3 Immunohistochemistry (IHC)

IHC was done according to normal laboratory routines with commercially available antibodies. In study V antigen retrieval was done by heating in a microwave oven. Secondary mAbs were peroxidase-bound, and diaminobenzidine was used as substrate. Known positive controls were included in every batch. In the FNAB study (III), cells were first sampled into cell culture medium, supplemented with albumin and penicillin and streptomycin at 4°C. Within an hour, cytocentrifuged preparations were made and stained with toluidine blue for immediate diagnosis. When the cells were abundant enough, preparations were made for immunohistochemical stainings. The slides were stored at -20°C after paraformaldehyde and acetone fixation according to the instructions given by the manufacturer of the mAbs .

Immunoreactions were done on 4 µm sections of formalin-fixed, paraffin-embedded tissue according to the manufacturer's instructions. The antibodies used, clone names and suppliers/manufacturers are listed in Table 3.

The immunoreaction in HER2 staining was considered positive when a brown membrane positivity was seen in the cancer cells (Fig.1 B, C, E, F in study V). Some tumours with very faint patchy staining were considered negative. In p53 staining, a brown staining of 10% or more of the nuclei of the cancer cells was regarded as positive. The cut-off point was chosen according to current literature on p53 (Ciesielski et al. 1995; Davidoff et al. 1991)

Table 3: Antibodies used in this work.

Name of epitope	Monoclonal=clone/polyclo nal	Source	Dilution used/ pretreatment
HER2 (study IV)	3B5	Oncogene Science, Inc, Manhasset, NY	1:10 (10µg/ml) pepsin pretreatment
HER2 (study V)	CB11	BioGenex, San Remon, CA. Ab no. 134M	1:50 microwave
Bcl-2	124	Daco, Corp. Glostrup, Denmark	1:40 microwave
p53 (study IV)	PAb 1801	Zymed Lab.Inc. San Francisco, CA	1:20 microwave
p53 (study V)	DO-7	Daco, Corp. Glostrup, Denmark	1:40 microwave
p21 <sup>ras</sup>	NCC-RAS-001	Daco, Corp. Glostrup, Denmark	1:40 No antigen retrieval
Ki-67	MIB-1	BioGenex, San Remon, CA	1:10 microwave
CD 44	DF 1485	Daco, Corp. Glostrup, Denmark	1:20 microwave
Fas/APO-1	Rabbit polyclonal	Zymed Lab.Inc. San Francisco, CA	1:50 microwave

#### ***6.4 Flow cytometry***

The flow cytometry in study II was done on a FACS IV cell sorter with a 60 µm diameter nozzle and an argon laser for excitation at 488 nm; 200mW total emission above 580 nm was measured (Becton-Dickinson FACS Systems, Mountainview, CA)

The cell suspensions in study III were analysed with a FACScan flow cytometer using the CellFit Cell Cycle analysis software programme for data acquisition and analysis (Becton Dickinson Immunocytometry Systems).

Chicken red cell nuclei were used for calibration of the instrumental settings before every measurement. The diploid G0/G1 peak of the cells analysed was at two times the channel number of the chicken RBC G0/G1 peak. Freshly prepared nuclei of HL-60 cells were analysed by the same channel (200). In both papers chicken red blood cells were also added to the specimens as internal controls.

The DNA-histograms were also analysed manually according to Baisch (Baisch and Gerdes 1987). The method with the lowest S-phase was used, and samples with background and/or many doublets were gated after collection of the primary data. No background subtraction was applied. List mode data were saved on diskettes for possible later re-evaluation. DNA indexes (DI) were considered diploid when there was only one peak at the same position as the G0/G1 peak of the nuclei of the HL-60 cell line and the DI calculated from the external and internal standards was 0.9-1.1. These diploid peaks were assigned a DI value of 1.00. When at least two separate G0/G1 peaks could be identified, the population

nearest to the channel of the G0/G1 peak of HL-60 nuclei was considered diploid, the DI of the other populations was measured using this peak as a reference.

The quality of the histograms was estimated by the coefficients of variation (CV) of the diploid G0/G1 peak. The manual model estimates the percent CV by determining the peak width at the inflection point of the peak, which occurs at approximately 60% of the peak height. The CVs of the aneuploid population's G0/G1 peaks were used to compare the two methods. The percentage of cells in SPF was estimated as the percentage of proliferating cells in the cell population with the greatest DI. When the G0/G1 peaks were so close to each other that their S-phases overlapped almost completely, a mean value was calculated for both populations.

The FNA material was injected into an ampoule containing sterile RPMI 1461 (3ml) supplemented with 10% human serum. When there was sufficient material in the FNAB, as measured from the firstly stained toluidine blue cytocentrifuged preparations, additional cells were pelleted by centrifugation and resuspended in 50µg/ml of Ethidium bromide (Sigma Chemical Co, cat. no E8751) in 10mM TRIS-EDTA buffer (pH 7.4) with 0.3% NP 40 and 1% RNase (Sigma Chemical Co) The sample was then passed through 50 m mesh nylon gauze and analysed by a FACScan4 flowcytometer.

Surgical specimens were immediately placed on ice, and frozen sections were made within 30min. If the tumour was diagnosed as malignant, an adjacent tumour section was snap frozen for later mechanical desegregation (mincing with a scalpel in cell culture medium on a Petri dish), followed by staining and analysis as described above for the FNAs.



Flow cytometry from archival material in study II was done on 50 µm thick paraffin sections that were deparaffined, rehydrated and lysed with proteinase K. The naked nuclei were stained with fluorescein-isothiocyanate as described above.

#### ***6.4 Statistical analysis***

Statistical analysis comprised the Chi-square test, Fisher's exact test, and Mann-Whitney rank-sum test, analysis of variance and Student's t-test. If the sample distribution was skewed, an appropriate transformation was used before testing. If there was a difference in group variance between the results for different parameters, as determined by Lewene's test, Welch statistics were used. The life table method and Mantel-Cox statistics estimated disease-free time and cumulative survival rates. All computations were done using BMDP statistical programs and a VAX 8600 computer (Dixon et al. 1983).

Differences between the groups were determined using Student's paired t-test. Regression plots were used to study the correlation between the differences in the SPF. Levene's test was also used to determine equality of the variances of the two sample acquisition methods.

## 7 Results

### *7.1 FNA:StudyIII*

The first aim of this study was to identify markers useful for preoperative prognostication. Fifteen years ago CNBs were not in common use, and FNAB was the leading method of preoperative diagnosis. A procedure was developed to make cell blocks from FNAB material, allowing IHC to be done on consecutive sections from the aspirated material (Krogerus and Andersson 1988). In many laboratories it may be easier to make direct smears or multiple cyto-centrifuge preparations than cell blocks for IHC, but also in such instances FNAB as well as CNB may be used (Railo et al. 1996).

The quality of flow cytometric histograms was found to be better from FNAB material than from tissue samples (III). There were more aneuploid peaks, on average, in the FNABs than in the surgical specimens, 33 vs. 23 aneuploid peaks out of 63 tumour samples. The correlation between SPA and the frequency of cells staining positively for Ki-67 was better in the FNAB material than in the surgical specimens.

The results of flow cytometry from the archival material largely confirmed what has been claimed by other investigators. Flow cytometry gave reliable information on cell kinetics and ploidy. This information was of prognostic value even in advanced breast cancer, but the prognostic power did not exceed that of the stage

or grade of the tumour.

### ***7.2 Lectin staining: Study I***

The staining pattern as well as staining intensity were recorded. It was concluded that there was more variability in the glucoconjugate composition of cells in the primary tumour than in the cells of the metastases. Also metastases from the same primary tumour could differ in their main lectin reactivity. Both the type and intensity of staining apparently changed during the process of metastasis. This may reflect clonal selection of the tumour cells to the metastatic site. Staining with fluorescent lectins was seen in the cell membrane and cytoplasm or in the nuclei.

### ***7.3 Proliferative epithelial lesions: Study V***

The IHC staining results with seven different mAbs, given in Table 3, in proliferative epithelial lesions were variable, and consistency was difficult to obtain within the lesions or between the same category of lesions. It was found, however, that the more atypical the lesion was, the more the results of the IHC staining diverged from the staining patterns of morphologically normal epithelium.

A lower reactivity for HER2 was seen in ADH than in papillomas, while DCIS stained more intensely than invasive cancer. In benign papillomas, the HER2 positivity associated significantly with a high percentage of staining for CD44.

The proliferative activity, as measured by MIB1 reactivity, was the highest in invasive ductal carcinoma and the lowest in papillomas. There was, however, great variability in proliferation activity among ductal carcinomas. A significant

difference in MIB1 stainings was seen only between ADH and DCIS3 ( $p < 0.05$ ).

In normal epithelium, CD44 staining was polarised, seen only in the baso-lateral membranes, at the epithelial-myo-epithelial junction. Normal epithelium stained more intensely than the malignant lesions, which showed a more haphazard distribution of staining for CD44. No significant difference in the total lengths of membranes staining positively was observed between the benign, pre-malignant and malignant categories of the lesions.

A positive immuno-staining for Fas was found in about one third of the cells in all types of lesions. The lowest intensity of staining was seen in papillomas.

The mAb for Ras p21 stained cells of both benign and malignant epithelium. The p21 staining was difficult to interpret due to extensive background staining.

DCIS3 and ductal carcinoma of grade III had the lowest frequency of positive cells (mean  $25 \pm 31\%$  (range 0-100) and  $25 \pm 35\%$  (range 0-100), respectively, and lobular carcinoma had the highest percentage ( $59 \pm 34\%$ , range 50-100).

In staining for bcl-2, the highest percentage of positive cells was seen in papillomas and lobular carcinomas ( $71 \pm 33\%$ , range 50-100 and  $70 \pm 36\%$ , range 50-100, respectively) and the lowest in DCIS3 ( $34 \pm 47\%$ , range 0-100). There was a tendency towards an inverse correlation between the staining intensities of p53 and bcl-2 in all groups of lesions.

In benign papillomas, HER2 positivity was frequently seen in cells staining for CD44.

#### ***7.4 Advanced breast cancer: Study II***

It was found that only 44% of the HER2-positive primary cancers and 29% of the HER2-negative primary cancers had HER2-positive metastases. This suggests that expression of HER2 may associate with metastatic propensity. The histologic grade of the primary cancer did not affect the HER2 status of the metastasis. Positive staining for HER2 in the primary cancer did not correlate with the ploidy or the SPF of the metastasis. HER2-positive metastases were more often ( $p < 0.04$ ) aneuploid (DNA index 1.7) than negative (mean DNA index 1.3). The proliferation activity was higher in the HER2-positive metastases (mean SPF 8.7%) than in the HER2-negative metastases (mean SPF of 5.6%), but this difference was not significant.

There was no concordance between HER2-positivity and p53-positivity in this material.

Patients with HER2-positive immunostaining of the primary tumours were free of cancer for an average of 1.6 years, and HER2-negative cancer patients, on an average of 2.0 years ( $p = 0.8$ ). When survival after recurrence was compared between patients with either a HER2-positive or -negative primary cancer, there was no significant difference between the two groups. HER2 did not correlate with the clinical stage or size of the primary tumour. In histological grade I cancers (23 patients), 80% of the patients with HER2-positive cancer survived for five years, but only 36% of the patients with HER2-negative cancer survived for five years.

The difference was, however, not quite significant ( $p=0.08$ ), study V.

When compared with the primary tumours, it was more common for the metastases to lose their positivity for HER2 than to gain it. In four cases a HER2-negative primary tumour had HER2-positive metastases. One of them was on the skin, one in the lung, and two in lymph nodes. The skin metastasis and one of the lymph node metastases were lobular cancers; the lung metastasis was a ductal cancer of grade II, and the other lymph node metastasis was a ductal cancer of grade I (study IV).

## 8 Discussion

The prognosis of breast cancer patients has improved during the course of this work (1996-2000) (Registry 1996; Rose'n et al. 2000). It is now apparent that most breast cancer patients benefit from adjuvant therapy, regardless of the presently used prognostic indexes ((EBCTCG). 1998a; (EBCTCG). 1998b). Patients with a favourable prognosis are nevertheless unnecessarily exposed to prolonged medication. Therefore, there is still a demand for better prognostication (Knorr et al. 1992; Rosen et al. 1992; Rosner and Lane 1993). The therapy has to be tailored individually for each patient, and that is why also predictive measures are needed (Klijn et al. 1993; Lavin et al. 1994; Rizzieri et al. 1999; Schaller et al. 1999).

Breast cancers are now found and treated at earlier stages, largely due to improved mammography equipment (Rose'n et al. 2000). This places demands on the diagnostic and therapeutic approaches. The ongoing discussion on the drawbacks

and benefits of FNAB contra CNB is one example of this change in attitudes (Florentine et al. 1997; Masood 1995; Sharifi et al. 1999; Troncone et al. 1995). Palpable tumours can be easily diagnosed with almost any method. The small tumour changes, targeted today by radiographic methods, need careful evaluation for the best diagnostic approach. All doctors taking part in the decision making on the treatment of breast cancer patients should therefore participate in the discussion on the diagnosis, prognosis and treatment of the patients.

It is important that the community treating breast cancer recognises that it is dealing with a disease of changing concepts. The measures taken to combat the disease are modulating the behaviour of the disease (studies I and IV) (Zambelli et al. 1999).

Several other investigators have evaluated some of the prognostic markers from preoperative cytological specimens. Most of these authors have succeeded in finding various cancer-related changes also in preneoplastic diseases (Gillett et al. 1998; Gupta et al. 1997; Lee 1995; Lucas et al. 2000; Pavelic et al. 1992; Siziopikou et al. 1996). Thus, many changes occurring alone in the genome are relatively innocent, but selection of a few critical changes probably initiates the cancerous transformation (Minami et al. 1998; Moreno et al. 1997; Murphy et al. 1995).

Lectin staining has shown that the surface glycoconjugate composition of the primary tumours was more heterogeneous than that of their metastases. This has been shown also by other investigators by other methods (Gisselsson et al. 2000; Könemann et al. 2000), but denied by others (Bonsing et al. 2000). Metastases from the same primary tumour to different locations in the body can display different patterns of lectin staining, implying that there are many clones in the

primary tumour, or that they can acquire different phenotypes in different locations (study I). This suggests that the metastatic process may involve a selection for sub-clones of tumour cells with better survival in a new environment.

Flow cytometry also showed that primary tumours frequently contained many cell lines with different ploidy and proliferation kinetics (studies II and III) (Joensuu et al. 1992). With FNAB, it is possible to enrich such populations for investigation, as compared to conventional sectioning and suspending the tumour material. Other investigators have confirmed this finding (Bach et al. 1991; Lorenzato et al. 2000a).

DI was strongly correlated with the grade, and probably therefore was not an independent prognosticator in breast cancer patients, as also shown by others (Blanco et al. 1990; Stanton et al. 1992; Toikkanen et al. 1989). Though the SPF gives reliable data on proliferation and has prognostic significance (Dressler et al. 1988; Toikkanen et al. 1989), proliferation can be measured equally reliably with IHC (Aaltomaa et al. 1992b; Gaglia et al. 1993).

Arnelöv and Auer used image cytometry and reported a good and independent correlation with DI and prognosis (Arnerlov et al. 1988; Fallenius et al. 1988; Feichter 1991; Feichter et al. 1988). Beerman demonstrated improved prognostic power of DI by grouping histograms into different prognostic classes (Beerman et al. 1990). The concept of histogram type has been successfully used also by others (Dieterich et al. 1995; Ferno et al. 1992). As in our studies, Tubiana found an agreement on the limitations of ploidy analysis in advanced stages of breast cancer (Tubiana et al. 1981).

The ICH obtained in this study from old archival material must be cautiously



interpreted. The fixation conditions of archival material are not always known. Variability has been addressed using large series with simultaneous staining, including negative and positive controls from the same batch. This makes reading of the results more reliable, since it is possible to make background subtraction, and subtraction for normal levels of staining (Battifora 1999).

Expression of HER2, and of many other proteins, may be lost or gained in the process of metastasis (study IV). HER2-positive metastases displayed aneuploidy more frequently and higher SPF than the HER2-negative metastases. It is possible that the HER2-positivity of the primary cancer is not a feature that favours the metastatic process; instead, the negative cell clones appeared to metastasise. This is in line with the fact that HER2 was less often expressed in the infiltrating than in the in situ component of a tumour. HER2 amplification is probably a sign, among others, of the tumour-promoting DNA instability. This concept is supported by the findings of a higher incidence of aneuploidy in the HER2-positive tumours and their metastases.

HER2-positivity has been correlated with metastases in axillary lymph nodes and with recurrence and visceral metastasis (Kallioniemi et al. 1991). An association between the expression of HER2 and the tumour type and tumour diameter as reported by Travis and his co-workers, could not be confirmed in this study (Travis et al. 1996). This study did not demonstrate that HER2 adds new prognostic information to breast cancer patient, as some investigators have shown (Lipponen et al. 1993a). There are, however, recent reports on the use of HER2 as a predictive marker of sensitivity to therapy (Cance and Liu 1995; Hudziak et al. 1988)

At advanced stages, grade 1, HER2-positive breast cancers are interesting. They often lack apparent other criteria for high grade malignancy, such as high SPF, aneuploidy, or p53 immunopositivity. However, in our material all of these (four cases) had an additional adverse prognostic marker, besides HER2, either in the primary tumour or in the metastasis.

Over-expression of HER2 has been studied mainly in primary tumours of the breast. Therefore, little information is available on the HER2 status in metastatic breast cancer. In the present study, 56% of the HER2-positive primary cancers had negative metastases, and, conversely, 29% of the HER2-negative primary cancers had positive metastases. This may be due to sampling error, since the study included large tumours, and only selected areas of the cancer were studied. Therefore HER2-positive clones in the primary HER2-negative cancers could be missed. Otherwise the findings suggest that during the process of metastatic spread, the cancer cells either lose HER2 over-expression or gain it.

Ductal cancers were more frequently p53- and CD44-positive and had higher proliferative activity than the lobular cancers. The DCISs were more frequently positive for p21, bcl-2 and HER2 (study V) than was LCIS. Among the invasive cancers, lobular cancers were more often positive for HER2 than were the ductal cancers. This might be a reflection of different behaviour in relation to the stroma (du Toit et al. 1991). The expression of HER2 showed an inverse correlation with the expression of adhesion molecule CD44. Thus, the HER2-positive tumours were less positive for CD44 than were the HER2-negative cancers of the same

histological type.

According to my results and those of others (Lucas et al. 2000), aberrant protein products are found in premalignant lesions as well as in overt cancers. There was only a slight difference in the quantity and the distribution, not the quality of the changes. The key difference between invasive and non-invasive tumour cell populations remains to be defined. The possibility remains that the difference is not inside the cells, but rather outside the cells, in the excreted enzymes and the periductular stroma, as suggested by numerous investigators (Foekens et al. 1992; Foekens et al. 1994; Foekens et al. 1993; Friedrichs et al. 1995; Frixen and Nagamine 1993; Gasparini et al. 1997; Janicke et al. 1993; Joensuu et al. 1995). An interesting molecule is tenascin-C, which appears around micro-invasive cell clusters (Jahkola et al. 1998; Jahkola et al. 1996).

The greatest challenge in prognostication, both for pre malignant and overtly malignant disease, lies in the heterogeneity of the lesions. Even if the genetic aberrations seems to go forward stepwise, the phenotypic diversity in different tissues, and even from cell to cell, is endless. It is not the primary tumour, but rather the metastatic disease that kills the patient. The ability to metastasise, to adhere to vital organs and thrive there, are the key features of a killing disease, as stated by Paget already at the end of the nineteenth century (Paget 1889).

First with the advent of oncogenes, then with more and more detailed understanding of cell division and its regulation, I have come to the conclusion that understanding cancer is like understanding chaos. It may be possible in theory, but not in detail. Instead of taking single parameters as single prognostic

factors, we have to think of the tumour as a society, with lots of individuals, and the more divergent the population is, the more potential it holds for destroying its host. Nicholson, in his discussion on the process of metastasis, concluded that the more aggressive metastatic clones had no means of emergin to something new, and to send metastases to other locations, as had the heterogeneous primary tumour (Nicolson 1982). It may of course be that chance alone decides how a cancer cell behaves in its next division, what devious behaviour it will gain, and that nothing in the cells predicts a malignant kind of behaviour.

## 9 Summary and conclusions

Breast cancer is the most significant malignancy of women in Western countries. Biologically the disease is heterogeneous and therefore unpredictable. It has unique features in its ability of dormancy and early metastasising. These features make the disease difficult to cure, and a large number of women live their lives in fear of the disease.

The purpose of this study was to find reasons for this unpredictability. In this study, tumour material from advanced disease as well as from early and pre-malignant disease were investigated with lectin staining, with flow cytometry and with IHC for oncogen products and proliferation markers. Primary tumours were compared with their metastases, and in situ components of the disease with the invasive components. Furthermore, diagnostic procedures, FNAB and histology, were compared with each other for diagnostic accuracy.

The primary tumours were more variable in their staining patterns than their corresponding metastases. Single parameters, like SPF, DI, hormone receptors, and single oncogene amplifications, did not predict the outcome in advanced disease. Deviations from normal epithelium seen in breast cancers were also found in pre-malignant disease. Additional markers for cellular changes, and probably also for extra-cellular alterations are to be identified, in order to target the crucial constellations of malignant behaviour.

FNAB proved to be better material for flow cytometry than surgically removed tissue, and FNAB was also useful for IHC. The investigated parameters gave useful information that may help in therapy decisions.

## 10 Acknowledgements

This work was carried out at the Department of Pathology, Haartman Institute, University of Helsinki. I want to thank the head of the department for the opportunity to complete this study and for the inspiring atmosphere prevailing in his laboratory and in all the laboratories in the Hartman Institute, especially the former transplantation laboratory.

I warmly thank my supervisor, Professor Leif Andersson, for many challenging ideas and for coping with me despite my stubbornness and slowness.

I want to thank the many wonderful women working in the laboratories, who taught me everything from cell culturing and immunohistochemistry to gel electrophoresis and flow cytometry. Thank you Hannele L, Hilikka Toivonen, Tuula Halmesvaara, Monna Shoulz and Last but not least our ever efficient ward führer in Maria pathology laboratory Anna-Leena Hästö.

I owe greatly to Docent Stig Nordling for arguing with me on hormone receptors and p-values and for having had the time and interest to read most of my papers before submission.

I wish to thank my co-authors Marja Leivonen and Mikael Railo as well as Monna, Anna-Leena and Stig for fruitful co-operation and support.

Docents Paula Martikainen and Ylermi Soini are thanked for fast and careful review of this thesis and expert advise.

I want to give special thanks to my colleagues Terttu Toivonen and Raija Malmi for never ending interest in and support of my work. I also remember with warmth all other friends and pathology colleagues at the pathology laboratory at Hartman Institute, with whom many happy hours were spent during hard work.

My heart beats for the pathology ward at Maria hospital, where the staff has always been with me in all my time consuming experimentation, never was there an aggressive voice despite enormous workloads. Everything I have asked for has always been done, so thank you Arja, Ulla, Bigi, Riitta, Tiina Anne, Irma, Gitta and Svenka.

I also want to thank an other inspiring working group in which I have had the honour to be a part: The trust in me that I have encountered At the 4<sup>th</sup> floor investigation laboratory at the Surgical hospital in Helsinki, especially Irmeli Lautenschlager has rendered me some of the self-confidence needed to fulfil this task.

Thank you dear Björn, Rasmus, Camilla, Niklas, Fanny, mother Maj-Lis, father Helge and family, neighbours and friends for giving me perspective to and enjoyment in life as a whole.

This work was financially supported by Finska läkaresällskapet, The Finnish Breast Cancer Group, The Ida Montin Foundation and the Paulo Foundation.

June 2001-06-27

LK

## 11 References

- (EBCTCG), E. B. C. T. C. G. (1998a). "Polychemotherapy for early breast cancer: an overview of the randomised trials." *Lancet*, 352, 930-42.
- (EBCTCG), E. B. C. T. C. G. (1998b). "Tamoxifen for early breast cancer: an overview of the randomised trials." *Lancet*, 351, 1451-67.
- Aaltomaa, S., Lipponen, P., Eskelinen, M., Alhava, E., and Syrjanen, K. (1991). "Nuclear morphometry and mitotic indexes as prognostic factors in breast cancer." *Eur J Surg*, 157(5), 319-24.
- Aaltomaa, S., Lipponen, P., Papinaho, S., Klemi, P., Kosma, V. M., Marin, S., Eskelinen, M., Alhava, E., and Syrjanen, K. (1992a). "Nuclear morphometry and DNA flow cytometry as prognostic factors in female breast cancer." *Eur J Surg*, 158(3), 135-41.
- Aaltomaa, S., Lipponen, P., and Syrjanen, K. (1992b). "Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining." *Anticancer Res*, 12(4), 1281-6.
- Aaltomaa, S., Lipponen, P., and Syrjanen, K. (1993). "Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer." *Anticancer Research*, 13(2), 533-8.
- Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. (1996). "Specific P53 mutations are

associated with de novo resistance to doxorubicin in breast cancer patients.” *Nature Medicine*, 2(7), 811-4.

Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., Zlotogora, J., Heching, N., and Peretz, T. (1997). “The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.” *Am J Hum Genet*, 60(3), 505-14.

Albain, K. S., Allred, D. C., and Clark, G. M. (1994). “Breast cancer outcome and predictors of outcome: are there age differentials?” *J Natl Cancer Inst. Monographs*(16), 35-42.

Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. (1993). “Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer [see comments].” *J Natl Cancer Inst*, 85(3), 200-6.

Allred, D. C., Clark, G. M., Molina, R., Tandon, A. K., Schnitt, S. J., Gilchrist, K. W., Osborne, C. K., Tormey, D. C., and McGuire, W. L. (1992). “Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.” *Hum Pathol*, 23(9), 974-9.

Anandappa, S. Y., Sibson, R., Platt-Higgins, A., Winstanley, J. H. R., Rudland, P. S., and Barraclough, R. (2000). “variant estrogen receptor alpha mRNAs in human breast cancer specimens.” *Int J Cancer*, 88, 209-16.



- Anbazhagan, R., Gelber, R. D., Bettelheim, R., Goldhirsch, A., and Gusterson, B. A. (1991). "Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer." *Ann Oncol*, 2(1), 47-53.
- Antman, K., and Shea, S. (1999). "Screening mammography under age 50." *JAMA*, 281(16), 1470-2.
- Arnerlov, C., Emdin, S. O., Roos, G., Angstrom, T., Bjersing, L., Angquist, K. A., Larsson, L. G., and Jonsson, H. (1988). "Prognostic factors in locally advanced breast cancer (T3, T4) with special reference to tumor cell DNA content." *Acta Oncol*, 27(3), 221-6.
- Arriagada, R., Rutqvist, L. E., Skoog, L., Johansson, H., and Kramar, A. (1992). "Prognostic factors and natural history in lymph node-negative breast cancer patients." *Breast Cancer Res Treat*, 21(2), 101-9.
- Azzopardi, J. G., Chepick, O. F., Hartmann, W. H., Jafarey, N. A., Llombart-Bosch, A., Ozzello, L., Rilke, F., Sasano, N., Sobin, L. H., Sommers, S. C., Stalsberg, H., Sugar, J., and Williams, A. O. (1981). *Histological typing of breast tumours*, WHO, Geneva.
- Bach, B. A., Knape, W. A., Edinger, M. G., and Tubbs, R. R. (1991). "Improved sensitivity and resolution in the flow cytometric DNA analysis of human solid tumor specimens. Use of in vitro fine-needle aspiration and uniform staining reagents." *Am J Clin Pathol*, 96(5), 675-27.
- Bacus, J. W., Boone, C. W., Bacus, J. V., Follen, M., Kelloff, G. J., Kagan, V., and Lippman, S. M. (1999). "Image morphometric nuclear grading of

intraepithelial neoplastic lesions with applications to cancer chemoprevention trials.” *Cancer Epidemiol Biomark Prev*, 8(12), 1087-94.

Bacus, S. S., Gudkov, A. V., Zelnick, C. R., Chin, D., Stern, R., Stancovski, I., Peles, E., Ben-Baruch, N., Farbstein, H., Lupu, R., Wen, D., Sela, M., and Yarden, Y. (1993). “Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.” *Cancer Res*, 53(21), 5251-61.

Baisch, H., and Gerdes, J. (1987). “Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry.” *Cell Tissue Kinet*, 20, 387-91.

Balslev, I., Axelsson, C. K., Zedeler, K., Rasmussen, B. B., Carstensen, B., and Mouridsen, H. T. (1994). “The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG).” *Breast Cancer Res Treat*, 32(3), 281-90.

Barbareschi, M. (1996). “Prognostic value of immunohistochemical expression of p53 in breast carcinomas. A review of the literature involving over 9,000 patients.” *App Immunohistochem*, 4, 106-16.

Bargou, R. C., Daniel, P. T., Mapara, M. Y., Bommert, K., Wagener, C., Kallinich, B., Royer, H. D., and Dorken, B. (1995). “Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis.” *Int J Cancer*, 60(6), 854-9.

- Barlund, M., Tirkkonen, M., Forozan, F., Tanner, M. M., Kallioniemi, O., and Kallioniemi, A. (1997). "Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions." *Genes Chromosomes Cancer*, 20(4), 372-6.
- Bataini, J. P., Picco, C., Martin, M., and Calle, R. (1978). "Relation between time - dose and local control of operable breast cancer treated by tumorectomy and radiotherapy or by radical radiotherapy alone." *Cancer*, 42(4), 2059-65.
- Battifora, H. (1999). "Quality assurance issues in immunohistochemistry." *J Histotech*, 22(3), 169-175.
- Battifora, H., Gaffey, M., Esteban, J., Mehta, P., Bailey, A., Faucett, C., and Niland, J. (1991). "Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases." *Mod Pathol*, 4(4), 466-74.
- Beerman, H., Kluin, P. M., Hermans, J., van de Velde, C. J., and Cornelisse, C. J. (1990). "Prognostic significance of DNA -ploidy in a series of 690 primary breast cancer patients." *International Journal of Cancer*, 45(1), 34-9.
- Berx, G., Cleton-Jansen, A. M., Nollet, F., de Leeuw, W. J., van de Vijver, M., Cornelisse, C., and van Roy, F. (1995). "E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers." *EMBO*, 14(24), 6107-15.
- Bianchi, S., Palli, D., and Ciatto, S. (1995). "Accuracy and reliability of frozen section diagnosis in a series of 672 nonpalpable breast lesions." *Am J Clin*

*Pathol*, 103, 199-205.

Bieche, I., Nogues, C., and Lidereau, R. (1999). "Overexpression of BRCA2 gene in sporadic breast tumours." *Oncogene*, 18(37), 5232-8.

Blamey, R. W., Davies, C. J., Elston, C. W., Johnson, J., Haybittle, J. L., and Maynard, P. V. (1979). "Prognostic factors in breast cancer -- the formation of a prognostic index." *Clin Oncol*, 5(3), 227-36.

Blanco, G., Holli, K., Heikkinen, M., Kallioniemi, O. P., and Taskinen, P. (1990). "Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading." *Br J Cancer*, 62(1), 142-6.

Blazyk, H., Hartman, A., Cunningham, J. M., Schaid, D., Wold, L. E., Kovach, J. S., and Sommer, S. S. (2000). "A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome." *Int J Cancer*, 89, 32-8.

Bloom, H. J. G., and Richardson, W. W. (1957). "Histological prognosis and grading in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years." *Br J Cancer*, 11, 359-77.

Boerner, S., and Sneige, N. (1998). "Specimen adequacy and false-negative diagnosis rate in fine-needle aspirates of palpable breast masses." *Cancer*, 84(6), 344-8.

Bondesson, L., and Lindholm, K. (1997). "Prediction of invasiveness by aspiration

cytology applied to nonpalpable breast carcinoma and tested in 300 cases.”

*Diagn cytopath*, 17(5), 315-20.

Bonnier, P., Romain, S., Charpin, C., Lejeune, C., Tubiana, N., Martin, P. M., and Piana, L. (1995a). “Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features.” *Int J Cancer*, 62(2), 138-44.

Bonnier, P., Romain, S., Giacalone, P. L., Laffargue, F., Martin, P. M., and Piana, L. (1995b). “Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy.” *Obst Gyn*, 85(1), 11-7.

Bonsing, B. A., Corver, W. E., Fleure, G. J., Cleton-Jansen, A. M., Devile, P., and Cornelisse, C. J. (2000). “Allelotype analysis of flow-sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases.” *Genes Chromosomes Cancer*, 28(2), 173-83.

Buerger, H., Otterbach, F., Simon, R., Schafer, K. L., Poremba, C., Diallo, R., Brinkschmidt, C., Dockhorn-Dworniczak, B., and Boecker, W. (1999). “Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes.” *J Pathol*, 189(4), 521-6.

Busmanis, I., Feleppa, F., Jones, A., McGrath, K. M., Reed, R., Collins, J., Russell, I., and Begley, C. G. (1994). “Analysis of cerbB2 expression using a panel of 6 commercially available antibodies.” *Pathology*, 26(3), 261-7.

- Cai, Z., Stancou, R., Korner, M., and Chouaib, S. (1996). "Impairment of Fas - antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells." *Int J Cancer*, 68(4), 535-46.
- Cance, W. G., and Liu, E. T. (1995). "Protein kinases in human breast cancer." *Breast Cancer Res & Treat*, 35(1), 105-14.
- Chamberlain, J. S., Boehnke, M., Frank, T. S., Kiouasis, S., Xu, J., Guo, S. W., Hauser, E. R., Norum, R. A., Helmbold, E. A., Markel, D. S., and et al. (1993). "BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis." *Am J Hum Genet*, 52(4), 792-8.
- Chan, V. T., and McGee, J. O. (1987). "Cellular oncogenes in neoplasia." *J Clin Pathol*, 40(9), 1055-63.
- Chariyalertsak, S., Thisuphakorn, P., and Ruangvejvorachai, P. (1999). "Correlation between immunohistochemical and biochemical estrogen receptors in the prognosis of patients with breast cancer." *Asian Pac J Allergy Immunol*, 17(2), 107-12.
- Ciatto, S., Bonardi, R., and Bianchi, S. (1992). "Nuclear grading and prognosis in node negative breast cancer." *Neoplasma*, 39(3), 167-70.
- Ciesielski, D., Dziewulska-Bokiniec, A., Zoltowska, A., Roszkiewicz, A., Kopacz, A., and Wojtacki, J. (1995). "p53 expression in breast cancer related to prognostic factors." *Neoplasma*, 42(5), 235-7.
- Clark, G. M. (1992a). "The biology of breast cancer in older women." *J Gerontol*,

47(Spec No), 19-23.

Clark, G. M. (1992b). "Integrating prognostic factors." *Breast Cancer Res Treat*, 22(3), 187-91.

Clark, G. M. (1994). "Do we really need prognostic factors for breast cancer?" *Breast Cancer Res Treat*, 30(2), 117-26.

Clark, G. M., and McGuire, W. L. (1983). "Prognostic factors in primary breast cancer." *Breast Cancer Res Treat*, 3(Suppl), S69-72.

Clark, G. M., and McGuire, W. L. (1989). "New biologic prognostic factors in breast cancer." *Oncology*, 3(5), 49-54.

Cockburn, J., Staples, M., Hurley, S. F., and De Luise, T. (1994). "Psychological consequences of screening mammography." *J Med Screen*, 1(1), 7-12.

Cote, R. J., Peterson, H. F., Chaiwun, B., Gelber, R. D., Goldhirsch, A., Castiglione-Gertsch, M., Gusterson, B., and Neville, A. M. (1999). "Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group." *Lancet*, 354(9182), 896-900.

Courdi, A., Hery, M., Dahan, E., Gioanni, J., Abbes, M., Monticelli, J., Ettore, F., Moll, J. L., and Namer, M. (1989). "Factors affecting relapse in node - negative breast cancer. A multivariate analysis including the labeling index." *Eur J Cancer Clin Oncol*, 25(2), 351-6.

Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J.,

- Seeburg, P. H., Libermann, T., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. (1985). "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene." *Science*, 230, 1132-9.
- Cowen, P. N., Teasdale, J., Jackson, P., and Reid, B. J. (1990). "Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay." *Histopathology*, 17(4), 319-25.
- Cox, C. E., Bass, S. S., McCann, C. R., Ku, N. N. K., Berman, C., Durand, K., Bolano, M., Wang, J., Peltz, E., Cox, S., Salud, C., Reintgen, D. S., and Lyman, G. H. (2000). "Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer." *Ann Rev Med*, 51, 525-42.
- Cressman, V. L., Backlund, D. C., Avrutskaya, A. V., Leadon, S. A., Godfrey, V., and Koller, B. H. (1999). "Growth retardation, DNA repair defects and lack of spermatogenesis in BRCA1-deficient mice." *Mol Cell Biol*, 19(10), 7061-75.
- Cwikla, J. B., Buscombe, J. R., Kolasinska, A. D., Parbhoo, S. P., Thakrar, D. S., and Hilson, A. J. (1999). "Correlation between uptake of Tc-99m sestamibi and prognostic factors of breast cancer." *Anticancer Res*, 19(3B), 2299-304.
- Davidoff, A. M., Herndon, J. E. d., Glover, N. S., Kerns, B. J., Pence, J. C., Iglehart, J. D., and Marks, J. R. (1991). "Relation between p53 overexpression and established prognostic factors in breast cancer." *Surgery*, 110(2), 259-64.



Davis, A. R. (1996). "Breast cancer: the search for new prognostic markers." *Br J Biomed Sci*, 53(2), 157-61.

de Jong, J. S., van Diest, P. J., and Baak, J. P. (2000). "Number of apoptotic cells as a prognostic marker in invasive breast cancer." *Br J Cancer*, 82(2), 368-73.

de la Rochefordiere, A., Asselain, B., Campana, F., Scholl, S. M., Fenton, J., Vilcoq, J. R., Durand, J. C., Pouillart, P., Magdelenat, H., and Fourquet, A. (1993). "Age as prognostic factor in premenopausal breast carcinoma." *Lancet*, 341(8852), 1039-43.

Depowski, P. L., Brien, T. P., Sheehan, C. E., Stylos, S., Johnson, R. L., and Ross, J. S. (1999). "Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer." *Am J Clin Pathol*, 112(4), 459-69.

Dhingra, K., and Hortobagyi, G. N. (1996). "Critical evaluation of prognostic factors." *Seminars in Oncology*, 23(4), 436-45.

Dhodapkar, M. V., Ingle, J. N., Cha, S. S., Mailliard, J. A., and Wieand, H. S. (1996). "Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials." *Cancer*, 77(4), 683-90.

Diel, I. D., Kaufman, M., Costa, S. D., Holle, R., vonMinkwitz, G., Solomayer, E. F., Kaul, S., and Bastert, G. (1996). "Micrometastatic breast cancer cells in

bone marrow at primary surgery: prognostic value in comparison with nodal status.” *J Natl Ca Inst*, 88(22), 1652-8.

Diel, I. J., Kaufmann, M., Goerner, R., Costa, S. D., Kaul, S., and Bastert, G.

(1992). “Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis.” *Journal of Clinical Oncology*, 10(10), 1534-9.

Dieterich, B., Albe, X., Vassilakos, P., Wieser, S., Friedrich, R., and Krauer, F.

(1995). “The prognostic value of DNA ploidy and S-phase estimate in primary breast cancer: a prospective study.” *Inte J Cancer*, 63(1), 49-54.

Dimitrakakis, C. E., Konstadoulakis, M. M., Kymionis, G. D., Manouras, A.,

Michalas, S., and Androulakis, G. (1999). “Does axillary dissection affect prognosis in T1 breast tumors?” *Eur J Gynaecol Oncol*, 20(5-6), 403-7.

Dixon, W. J., Brown, M. B., Engelman, L., Frane, J. W., Hill, M. A., Jennrich, R.

I., and Toporek, J. D. (1983). *BMDP statistical software*, , Los Angeles.

Dressler, L. G., Seamer, L. C., Owens, M. A., Clark, G. M., and McGuire, W. L.

(1988). “DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens.” *Cancer*, 61(3), 420-7.

du Toit, R. S., Locker, A. P., Ellis, I. O., Elston, C. W., Nicholson, R. I.,

Robertson, J. F., and Blamey, R. W. (1991). “An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast.” *Eur J Surg Oncol*, 17(3), 251-7.

- Dupont, W., and Page, D. (1985). "Risk factors for breast cancer in women with proliferative breast disease." *NEJM*, 312, 146-51.
- Dupont, W. D., and Page, D. L. (1989). "Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia." *Hum Pathol*, 20, 723-5.
- Elledge, R. M., and Allred, D. C. (1994). "The p53 tumor suppressor gene in breast cancer." *Breast Cancer Res Treat*, 32(1), 39-47.
- Ellis, I. O., Hinton, C. P., MacNay, J., Elston, C. W., Robins, A., Owainati, A. A., Blamey, R. W., Baldwin, R. W., and Ferry, B. (1985). "Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator." *Br Med J Clin Res Ed.*, 290(6472), 881-3.
- Elston, C. W. (1984). "The assessment of histological differentiation in breast cancer." *Aust New Zeal J Surg*, 54(1), 11-5.
- Elston, C. W., and Ellis, I. O. (1998). *The breast*, Churchill Livingstone, Bath.
- Eng, C., and Ponder, B. A. (1993). "The role of gene mutations in the genesis of familial cancers." *FASEB*, 7(10), 910-9.
- Engin, K. (1994). "Prognostic factors in bilateral breast cancer." *Neoplasma*, 41(6), 353-7.
- Falkson, G., Gelman, R. S., and Pretorius, F. J. (1986). "Age as a prognostic factor in recurrent breast cancer." *J Clin Oncol*, 4(5), 663-71.

- Fallenius, A. G., Franzen, S. A., and Auer, G. U. (1988). "Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphologic factors. A retrospective study of 227 consecutive cases." *Cancer*, 62(3), 521-30.
- Feichter, G. E. (1991). "Flow cytometry of breast cancer." *Zentralblatt Pathol*, 137(3), 220-6.
- Feichter, G. E., Mueller, A., Kaufmann, M., Haag, D., Born, I. A., Abel, U., Klinga, K., Kubli, F., and Goerttler, K. (1988). "Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer." *Int J Cancer*, 41(6), 823-8.
- Fenlon, S., Ellis, I. O., Bell, J., Todd, J. H., Elston, C. W., and Blamey, R. W. (1987). "Helix pomatia and Ulex europeus lectin binding in human breast carcinoma." *J Pathol*, 152(3), 169-76.
- Ferno, M., Baldetorp, B., Borg, A., Olsson, H., Sigurdsson, H., and Killander, D. (1992). "Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome." *Acta Oncol*, 31(2), 157-65.
- Ferreiro, J. A., Gisvold, J. J., and Bostwick, D. G. (1995). "Accuracy of frozen - section diagnosis of mammographically directed breast biopsies. Results of 1490 consecutive cases." *Am J Surg Pathol*, 19, 1267-71.
- Fidler, I. J. (1973). "Selection for successive tumor lines for metastasis." *Nature New Biol*, 242, 148-149.

- Fisher, E. R., Costantino, J., Fisher, B., Palekar, A. S., Paik, S. M., Suarez, C. M., and Wolmark, N. (1996). "Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ." *Cancer*, 78(7), 1403-16.
- Fisher, E. R., Dignam, J., Tan-Chiu, E., Costantino, J., Fisher, B., Paik, S., and Wolmark, N. (1999). "Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma." *Cancer*, 86(3), 429-38.
- Florentine, B. D., Cobb, C. J., Frankel, K., Greaves, T., and Martin, S. E. (1997). "Core needle biopsy: a useful adjunct to fine needle aspiration in select patients with palpable breast lesions." *Cancer*, 81, 33-9.
- Foekens, J. A., Schmitt, M., van Putten, W. L., Peters, H. A., Bontenbal, M., Janicke, F., and Klijn, J. G. (1992). "Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients." *Cancer Res*, 52(21), 6101-5.
- Foekens, J. A., Schmitt, M., van Putten, W. L., Peters, H. A., Kramer, M. D., Janicke, F., and Klijn, J. G. (1994). "Plasminogen activator inhibitor-1 and prognosis in primary breast cancer." *J Clin Oncol*, 12(8), 1648-58.
- Foekens, J. A., van Putten, W. L., Portengen, H., de Koning, H. Y., Thirion, B., Alexieva-Figusch, J., and Klijn, J. G. (1993). "Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis." *J Clin Oncol*, 11(5), 899-908.

- Friedman, L. S., Ostermeyer, E. A., Lynch, E. D., Welch, P., Szabo, C. I., Meza, J. E., Anderson, L. A., Dowd, P., Lee, M. K., Rowell, S. E., and et al. (1995). "22 genes from chromosome 17q21: cloning, sequencing, and characterization of mutations in breast cancer families and tumors." *Genomics*, 25(1), 256-63.
- Friedrichs, K., Ruiz, P., Franke, F., Gille, I., Terpe, H. J., and Imhof, B. A. (1995). "High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival." *Cancer Res*, 55(4), 901-6.
- Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Lochner, D., and Birchmeier, W. (1991). "E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells." *J Cell Biol*, 113(1), 173-85.
- Frixen, U. H., and Nagamine, Y. (1993). "Stimulation of urokinase-type plasminogen activator expression by blockage of E-cadherin-dependent cell-cell adhesion." *Cancer Res*, 53(15), 3618-23.
- Gaglia, P., Bernardi, A., Venesio, T., Caldarola, B., Lauro, D., Cappa, A. P., Calderini, P., and Liscia, D. S. (1993). "Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences [see comments]." *Eur J Cancer*, 29A(11), 1509-13.
- Gajdos, C., Levy, M., Herman, Z., Herman, G., Bleiweiss, I. J., and Tartter, P. I. (1999). "Complete removal of nonpalpable breast malignancies with a stereotactic percutaneous vacuum-assisted biopsy instrument [see comments]." *J Am Coll Surg*, 189(3), 237-40.

- Galea, M. H., Blamey, R. W., Elston, C. E., and Ellis, I. O. (1992). "The Nottingham Prognostic Index in primary breast cancer." *Breast Cancer Res Treat*, 22(3), 207-19.
- Garcia, J. M., Silva, J. M., Dominguez, G., Gonzalez, R., Navarro, A., Carretero, L., Provencio, M., Espana, P., and Bonilla, F. (1999). "Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype." *Breast Cancer Res Treat*, 57(3), 237-43.
- Gasparini, G., Toi, M., Gion, M., Verderio, P., Dittadi, R., Hanatani, M., Matsubara, I., Vinante, O., Bonoldi, E., Boracchi, P., Gatti, C., Suzuki, H., and Tominaga, T. (1997). "Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma." *J Natl Cancer Inst*, 89(2), 139-47.
- Gillett, C., Lee, A., Millis, R., and Barnes, D. (1998). "Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia." *J Pathol*, 184(4), 396-400.
- Gisselsson, D., Pettersson, L., Höglund, M., Heidenblad, M., Gorunova, L., Wiegant, J., Mertens, F., Dal Cin, P., Mitelman, F., and Mandahl, N. (2000). "Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity." *Proc Natl Acad Sci*, 97(10), 5357-62.
- Godolphin, W., Elwood, J. M., and Spinelli, J. J. (1981). "Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients." *Int J Cancer*, 28(6), 677-83.

- Goldgar, D. E., Cannon-Albright, L. A., Oliphant, A., Ward, J. H., Linker, G., Swensen, J., Tran, T. D., Fields, P., Uharriet, P., and Skolnick, M. H. (1993). "Chromosome 17q linkage studies of 18 Utah breast cancer kindreds." *Am J Hum Genet*, 52(4), 743-8.
- Goldgar, D. E., Fields, P., Lewis, C. M., Tran, T. D., Cannon-Albright, L. A., Ward, J. H., Swensen, J., and Skolnick, M. H. (1994). "A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis." *Jo Natl Cancer Inst*, 86(3), 200-9.
- Goldgar, D. E., Neuhausen, S. L., Steele, L., Fields, P., Ward, J. H., Tran, T., Ngyuen, K., Stratton, M. R., and Easton, D. F. (1995). "A 45 -year follow-up of kindred 107 and the search for BRCA2." *J Natl Cancer Inst. Monographs*(17), 15-9.
- Gonzalez, R., Silva, J. M., Dominguez, G., Garcia, J. M., Martinez, G., Vargas, J., Provencio, M., Espana, P., and Bonilla, F. (1999). "Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations." *Br J Cancer*, 81(3), 503-9.
- Gotteland, M., May, E., May-Levin, F., Contesso, G., Delarue, J. C., and Mouriesse, H. (1994). "Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents." *Cancer*, 74(3), 864-71.
- Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. (1997). "ErbB -2, the preferred heterodimerization partner of all ErbB receptors is amediator of lateral signaling." *EMBO J*, 16, 1647-55.



- Greenberg, E. R., Vessey, M. P., McPherson, K., Doll, R., and Yeates, D. (1985). "Body size and survival in premenopausal breast cancer." *Br J Cancer*, 51(5), 691-7.
- Groenendijk, R. P., Bult, P., Tewarie, L., Peer, P. G., van der Sluis, R. F., Ruers, T. J., and Wobbes, T. (2000). "Screen -detected breast cancers have a lower mitotic activity index." *Br J Cancer*, 82(2), 381-4.
- Guenther, J. M. (1999). "Axillary dissection after unsuccessful sentinel lymphadenectomy for breast cancer." *Am Surg*, 65(10), 991-4.
- Gupta, S., Douglas-Jones, A., Fenn, N., Morgan, J., and Mansell, R. (1997). "The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ)." *Cancer*, 80, 1740-5.
- Hansen, R. K., and Bissell, M. J. (2000). "Tissue architecture and breast cancer: the role of ECM and steroid hormones." *Endocrine-Related Cancer*, 7, 95-113.
- Harris, C. C. (1996). "Structure and function of p53 tumor suppressor gene: clues for rational cancer therapeutic strategies." *J Nat Cancer Inst*, 88, 1442-55.
- Harris, J. R., Lippmann, M. E., Veronesi, U., and Villett, W. (1992). "Breast cancer: Adjuvant therapy of breast cancer." *N Engl J Med*, 327, 473-80.
- Hazan, R. B., Phillips, G. R., Qiao, R. F., Norton, L., and Aaronson, S. A. (2000). "Exogenous expression of N-cadherin in breast cancer cells induces cell migration , invasion , and metastasis." *J Cell Biol*, 148(4), 779-90.

- Hellemans, P., van Dam, P. A., Geyskens, M., van Oosterom, A. T., Buytaert, P., and Van Marck, E. (1995). "Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast." *J Clin Pathol*, 48(2), 147-50.
- Hermanek, P., Hutter, R. V. P., Sobin, L. H., Wagner, G., and Wittekind, C. (1997). "TNM Atlas. Illustrated guide to the TNM/pTNM classification of malignant tumours." UICC, U. I. C. I. Cancer, ed., Springer, Berlin.
- Hermansen, C., Skovgaard-Poulsen, H., Jensen, J., Langfeldt, B., Steenskov, V., Frederiksen, P., and Myhre-Jensen, O. (1984). "Palpable breast tumours: "triple diagnosis" and operative strategy." *Acta Chir Scand*, 150(8), 625-8.
- Hudziak, R. M., Lewis, G. D., Shalaby, M. R., Eessalu, T. E., Aggarwal, B. B., Ullrich, A., and Shepard, H. M. (1988). "Amplified expression of the HER2/ERBB2 oncogene induces resistance to." *Proc Natl Acad Sci U S A*, 85(14), 5102-6.
- Iida, N., and Bourguignon, L. (1995). "New CD44 splice variants associated with human breast cancers." *J Cell Physiol*, 162(1), 127-33.
- Jahkola, T., Toivonen, T., Nordling, S., Smitten, K. v., and Virtanen, I. (1998). "Expression of tenascin -C in intraductal carcinoma of human breast: Relationship to invasion." *Eur J Cancer*, 34(11), 1687-1692.
- Jahkola, T., Toivonen, T., Smitten, K. v., Blomqvist, C., and Virtanen, I. (1996). "Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis." *Int J Cancer*, 69, 445-447.

- Janicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Hofler, H., and Graeff, H. (1993). "Urokinase (uPA) and its inhibitor PAI -1 are strong and independent prognostic factors in node-negative breast cancer." *Breast Cancer Res Treat*, 24(3), 195-208.
- Jarvinen, T. A., Tanner, M., Rantanen, V., Barlund, M., Borg, A., Grenman, S., and Isola, J. (2000a). "Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification." *Am J Pathol*, 156(3), 839-47.
- Jarvinen, T. A. H., Peltö-Huikko, M., Holli, K., and Isola, J. (2000b). "Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade and proliferation rate in breast cancer." *Am J Pathol*, 156, 29-35.
- Jatoi, I. (1999). "Management of the axilla in primary breast cancer." *Surg Clin North Am*, 79(5), 1061-73.
- Joensuu, H., Alanen, K., Falkmer, U. G., Klemi, P., Nordling, S., Remvikos, Y., and Toikkanen, S. (1992). "Effect of DNA ploidy classification on prognosis in breast cancer." *Int J Cancer*, 52(5), 701-6.
- Joensuu, H., Pylkkanen, L., and Toikkanen, S. (1994). "Bcl-2 protein expression and long-term survival in breast cancer." *Am J Pathol*, 145(5), 1191-8.
- Joensuu, H., and Toikkanen, S. (1991). "Prognosis of breast cancer with small primary tumor (pT1)." *Acta Oncol*, 30(7), 793-6.
- Joensuu, H., and Toikkanen, S. (1992). "Identification of subgroups with favorable

prognosis in breast cancer.” *Acta Oncol*, 31(3), 293-301.

Joensuu, H., Toikkanen, S., and Isola, J. (1995). “Stromal cell cathepsin D expression and long-term survival in breast cancer.” *Br J Cancer*, 71(1), 155-9.

Kallioniemi, A., Kallioniemi, O. P., Piper, J., Tanner, M., Stokke, T., Chen, L., Smith, H. S., Pinkel, D., Gray, J. W., and Waldman, F. M. (1994). “Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.” *Proc Natl Acad Sci*, 91, 2156-2160.

Kallioniemi, O. P., Blanco, G., Alavaikko, M., Hietanen, T., Mattila, J., Lauslahti, K., and Koivula, T. (1987). “Tumour DNA ploidy as an independent prognostic factor in breast cancer.” *Br J Cancer*, 56(5), 637-42.

Kallioniemi, O. P., Blanco, G., Alavaikko, M., Hietanen, T., Mattila, J., Lauslahti, K., Lehtinen, M., and Koivula, T. (1988). “Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.” *Cancer*, 62(10), 2183-90.

Kallioniemi, O. P., Holli, K., Visakorpi, T., Koivula, T., Helin, H. H., and Isola, J. (1991). “Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.” *Int J Cancer*, 49, 650-655.

Kallioniemi, O.-P., Kärkkäinen, A., Mattila, J., Auvinen, O., Koivula, T., and Hakama, M. (1989). “Mammografiasulonnassa todettavien rintasyöpien

ominaisuudet-virtaussytometrinen tutkimus.” *Duodecim*, 105(11), 1532-1538.

Kamarainen, M., Seppala, M., Virtanen, I., and Andersson, L. C. (1997).

“Expression of glycodeilin in MCF-7 breast cancer cells induces differentiation into organized acinar epithelium.” *Lab Invest*, 77(6), 567-73.

Karrison, T. G., Ferguson, D. J., and Meier, P. (1999). “Dormancy of mammary carcinoma after mastectomy.” *J Natl Ca Inst*, 91(1), 80-5.

Kerlikowske, K., Grady, D., Rubin, S. M., Sandrock, C., and Ernster, V. L.

(1995). “Efficacy of screening mammography. A meta-analysis.” *JAMA*, 273(2), 149-154.

Klemi, P. J., Joensuu, H., Toikkanen, S., Tuominen, J., Räsänen, O., Tyrkkö, J., and Parvinen, I. (1992). “Aggressiveness of breast cancers found with and without screening.” *BMJ*, 304, 467-469.

Klijn, J. G., Berns, E. M., Bontenbal, M., and Foekens, J. (1993). “Cell biological factors associated with the response of breast cancer to systemic treatment.” *Cancer Treat Rev*, 19(Suppl B), 45-63.

Knight, W. A., Livingston, R. B., Gregory, E. J., and McGuire, W. L. (1977).

“Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.” *Cancer Res*, 37(12), 4669-71.

Knorr, K. L., Hilsenbeck, S. G., Wenger, C. R., Pounds, G., Oldaker, T., Vendely,

- P., Pandian, M. R., Harrington, D., and Clark, G. M. (1992). "Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients." *Breast Cancer Res Treat*, 22(3), 251-62.
- Knuutila, S., Aalto, Y., Autio, K., Björkqvist, A.-M., El-Rifai, W., Hemmer, S., Huhta, T., Kettunen, E., Kiuru-Kuhlefelt, S., Larramendy, M. L., Lushnikova, T., Monni, O., Pere, H., Tapper, J., Tarkkanen, M., Varis, A., Wasenius, V.-M., Wolf, M., and Zhu, Y. (1999). "DNA copy number losses in human neoplasms." *Am J Path*, 155, 683-694.
- Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O.-P. (1998). "Tissue microarrays for high-throughput molecular profiling of tumor specimens." *Nat Med*, 4(7), 844-7.
- Korzeniowski, S., and Dyba, T. (1994). "Reproductive history and prognosis in patients with operable breast cancer [see comments]." *Cancer*, 74(5), 1591-4.
- Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V. M., Niskanen, E., Nordling, S., and Reed, J. C. (1995). "Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma." *Cancer Res*, 55(19), 4471-8.
- Kreula, J. (1990). "A new method for investigating the sampling technique of fine needle aspiration biopsy." *Invest Radiol*, 25(3), 245-9.

- Krogerus, L. A., and Andersson, L. C. (1988). "A simple method for the preparation of paraffin-embedded cellblocks from fine needle aspirates, effusions and brushings." *Acta Cytol*, 32(4), 585-7.
- Könemann, S., Schuck, A., Malath, J., Rupek, T., Horn, K., Baumann, M., Vormoor, J., Rube, C., and Willich, N. (2000). "Cell heterogeneity and subpopulations in solid tumors characterized by simultaneous immunophenotyping and DNA content analysis." *Cytometry*, 41, 172-7.
- Lam, P. B., Vacek, P. M., Geller, B. M., and Muss, H. B. (2000). "The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont." *Cancer*, 89, 369-75.
- Lavin, M. F., Bennett, I., Ramsay, J., Gardiner, R. A., Seymour, G. J., Farrell, A., and Walsh, M. (1994). "Identification of a potentially radiosensitive subgroup among patients with breast cancer." *J Natl Cancer Inst*, 86(21), 1627-34.
- Le Doussal, V., Tubiana-Hulin, M., Friedman, S., Hacene, K., Spyrtos, F., and Brunet, M. (1989). "Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas." *Cancer*, 64(9), 1914-21.
- le Doussal, V., Tubiana-Hulin, M., Hacene, K., Friedman, S., and Brunet, M. (1989). "Nuclear characteristics as indicators of prognosis in node negative breast cancer patients." *Breast Cancer Res Treat*, 14(2), 207-16.

- Lee, A. K., DeLellis, R. A., Silverman, M. L., and Wolfe, H. J. (1986).  
 “Lymphatic and blood vessel invasion in breast carcinoma: a useful  
 prognostic indicator?” *Hum Pathol*, 17(10), 984-7.
- Lee, C. K., and Carter, D. (1995). “Detecting residual tumor after excisional  
 biopsy of inpalpable breast carcinoma Efficacy of comparing preoperative  
 mammograms with radiographs of the biopsy specimen.” *AJC*, 164, 81-6.
- Lee, E. Y. (1995). “Tumor suppressor genes and their alterations in breast cancer.”  
*Semin Cancer Biol*, 6(3), 119-25.
- Lesser, M. L., Rosen, P. P., and Kinne, D. W. (1982). “Multicentricity and  
 bilaterality in invasive breast carcinoma.” *Surgery*, 1, 234-40.
- Li, S., Ting, N. S., Zheng, L., Chen, P. L., Ziv, Y., Shiloh, Y., Lee, E. Y., and  
 Lee, W. H. (2000). “Functional link of BRCA1 and ataxia telangiectasia  
 gene product in DNA damage response.” *Nature*, 406(6792), 210-5.
- Linell, F., Andersen, J., and Carter, D. (1986). “A symposium on sclerosing duct  
 lesions of the breast.” *Pathol Annu*, 21, 145-79.
- Lipponen, H. J., Aaltomaa, S., Syrjanen, S., and Syrjanen, K. (1993a). “c-erbB-2  
 oncogene related to p53 expression, cell proliferation and prognosis in  
 breast cancer.” *Anticancer Res*, 13(4), 1147-52.
- Lipponen, P., Ji, H., Aaltomaa, S., Syrjanen, S., and Syrjanen, K. (1993b). “p53  
 protein expression in breast cancer as related to histopathological  
 characteristics and prognosis.” *Int J Cancer*, 55(1), 51-6.



- Lipponen, P., Pietiläinen, T., Kosma, V.-M., Aaltomaa, S., Eskelinen, M., and Syrjänen, K. (1995). "Apoptosis suppressing protein bcl -2 is expressed in well-differentiated breast carcinomas with favorable prognosis." *J Pathol*, 177, 49-55.
- Lorenzato, M., Abbou, P., Masure, M., Bouttens, D., Visseaux-Coletto, B., Quereux, C., and Adne, J. J. (2000a). "Image cytometry detection of breast cancer cells with > 5C DNA content and minor DNA stemlines." *Anal Quant Cytol Histol*, 22(3), 199-205.
- Lorenzato, M., Abboud, P., Lechki, C., Browarnyj, F., O'Donohue, M. F., Ploton, D., and Adnet, J. J. (2000b). "Proliferation assessment in breast cancer: a double-staining technique for AgNOR quantification in MIB-1 positive cells especially adapted for image cytometry." *Micron*, 31(2), 151-9.
- Lu, P. J., Lu, Q. L., Rughetti, A., and Taylor-Papadimitriou, J. (1995). "bcl -2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis of human mammary epithelial cells [published erratum appears in J Cell Biol 1995 Nov;131(4):following 1121]." *J Cell Biol*, 129(5), 1363-78.
- Lucas, J., Niu, N., and Press, M. F. (2000). "p53 mutations and expression in breast carcinoma in situ." *Am J Pathol*, 156, 183-191.
- Luna-More, S., de los Santos, F., Breton, J. J., and Canadas, M. A. (1996). "Estrogen and progesterone receptors, c -erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas." *Pathol Res Pract*, 192(1), 27-32.

- Luu, H. H., Otis, C. N., Reed, W. P., Jr., Garb, J. L., and Frank, J. L. (1999). "The unsatisfactory margin in breast cancer surgery." *Am J Surg*, 178(5), 362-6.
- Macgregor, J. I., and Jordan, V. C. (1998). "Basic guide to the mechanisms of antiestrogen action." *Pharmacol Rev*, 50(2), 151-96.
- Malik, H. Z., George, W. D., Mallon, E. A., Harnett, A. N., Macmillan, R. D., and Purushotham, A. D. (1999). "Margin assessment by cavity shaving after breast-conserving surgery: analysis and follow-up of 543 patients." *Eur J Surg Oncol*, 25(5), 464-9.
- Mandelson, M. T., Oestreicher, N., Porter, P. L., White, D., Finder, C. A., Taplin, S. H., and White, E. (2000). "Breast density as a predictor of mammographic detection: Comparison of interval- and screen-detected cancer." *J Natl Cancer inst*, 92(13), 1081-7.
- Mann, G. B., Port, E. R., Rizza, C., Tan, L. K., Borgen, P. I., and Van Zee, K. J. (1999). "Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma." *Ann Surg Oncol*, 6(6), 591-8.
- Marcus, J. N., Watson, P., Page, D. L., and Lynch, H. T. (1994). "Pathology and heredity of breast cancer in younger women." *J Natl Cancer Inst. Monographs*(16), 23-34.
- Marson, L. P., Kurian, K. M., Miller, W. R., and Dixon, J. M. (1999). "Reproducibility of microvessel counts in breast cancer specimens." *Br J Cancer*, 81(6), 1088-93.

- Martegani, M. P., Del Pretew, F., Gasbarri, A., Natali, P. G., and Bartolazzi, A. (1999). "Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant e3xon products." *Am J Pathol*, 154(1), 291-300.
- Maskarinec, G. (2000). "Breast cancer --interaction between ethnicity and environment." *In Vivo*, 14(1), 115-23.
- Mason, B. H., Holdaway, I. M., Stewart, A. W., Neave, L. M., and Kay, R. G. (1990). "Season of tumour detection influences factors predicting survival of patients with breast cancer." *Breast Cancer Res Treat*, 15(1), 27-37.
- Masood, S. (1995). "Prognostic factors in breast cancer: use of cytologic preparations." *Diagn Cytopath*, 13(5), 388-95.
- Mathiesen, O., Bonderup, O., Carl, J., Panduro, J., and Pedersen, K. O. (1991). "The prognostic value of estrogen and progesterone receptors in female breast cancer. A single center study." *Acta Oncol*, 30(6), 691-5.
- McCready, D. R., Bodurtha, A. J., Davis, N. L., Meterissian, S., Robert, J., and Temple, W. J. (1999). "Sentinel lymph-node biopsy in breast cancer." *Can J Surg*, 42(6), 406-7.
- McDevitt, R. W., Stevens, J. A., and Lee, N. C. (1992). "Histologic types of benign breast disease and the risk for breast cancer." *Cancer*, 69, 1408-14.
- McGuckin, M. A., Cummings, M. C., Walsh, M. D., Hohn, B. G., Bennett, I. C., and Wright, R. G. (1996). "Occult axillary node metastases in breast

cancer: their detection and prognostic significance.” *British Journal of Cancer*, 73(1), 88-95.

McGuire, W. L., and Clark, G. M. (1992). “Prognostic factors and treatment decisions in axillary-node-negative breast cancer [see comments].” *New England Journal of Medicine*, 326(26), 1756-61.

McGuire, W. L., Clark, G. M., Dressler, L. G., and Owens, M. A. (1986). “Role of steroid hormone receptors as prognostic factors in primary breast cancer.” *NCI Monographs*(1), 19-23.

Menard, S., Bufalino, R., Rilke, F., Cascinelli, N., Veronesi, U., and Colnaghi, M. I. (1994). “Prognosis based on primary breast carcinoma instead of pathological nodal status.” *Br J Cancer*, 70(4), 709-12.

Merkel, D. E., and Osborne, C. K. (1989). “Prognostic factors in breast cancer.” *Hematology - Oncology Clinics of North America*, 3(4), 641-52.

Meyn, R. E., Stephens, L. C., Mason, K. A., and Medina, D. (1996). “Radiation - induced apoptosis in normal and pre-neoplastic mammary glands in vivo: significance of gland differentiation and p53 status.” *Int J Cancer*, 65(4), 466-72.

Miller, A. B., To, T., Baines, C. J., and Wall, C. (2000). “Canadian national breast screening study-2: 13-year results in a randomized trial in women aged 50-59 years.” *J Natl Ca Inst*, 92, 1490-9.

Minami, Y., Ochuchi, N., Taeda, Y., Fukao, A., and Hisamichi, S. (1998). “Risk

factors for benign breast disease according to histopathological type:

Comparisons for risk factors for breast cancer.” *Jpn J Cancer Res*, 89, 116-23.

Moot, S. K., Peters, G. N., and Cheek, J. H. (1987). “Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma.” *Cancer*, 60(3), 382-5.

Moreno, A., Lloveras, B., Figueras, A., Escobedo, A., Ramon, J., Sierra, A., and Fabra, A. (1997). “Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.” *Mod Pathol*, 10, 1088-92.

Morris, A., Pommier, R. F., Schmidt, W. A., Shih, R. L., Alexander, P. W., and Vetto, J. T. (1998). “Accurate evaluation of palpable breast masses by the triple test score.” *Arch Surg*, 133(9), 930-4.

Moss, S. M., Ellman, R., Coleman, D., and Chamberlain, J. (1994). “Survival of patients with breast cancer diagnosed in the United Kingdom trial of early detection of breast cancer. United Kingdom Trial of Early Detection of Breast Cancer Group.” *J Med Screen*, 1(3), 193-8.

Mouridsen, H. T., Andersen, J., Andersen, K. W., Axelsson, C., Blichert-Toft, M., Dombernowsky, P., Hansen, M., Krag, C., Overgard, M., Rasmussen, B. B., and et al. (1992). “Classical prognostic factors in node -negative breast cancer: the DBCG experience.” *J Natl Cancer Inst. Monographs*(11), 163-6.

- Murphy, D. S., Hoare, S. F., Going, J. J., Mallon, E. E., George, W. D., Kaye, S. B., Brown, R., Black, D. M., and Keith, W. N. (1995). "Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis." *J Natl Cancer Inst*, 87(22), 1694-704.
- Nagafuchi, A., Ishihara, S., and Tsukita, S. (1994). "The roles of catenins in the cadherin-mediated cell adhesion: functional analysis of E-cadherin-a-catenin fusion molecules." *J Cell Biol*, 127, 235-45.
- Nathan, B., Gusterson, B., Jadayel, D., O'Hare, M., Anbazhagan, R., Jayatilake, H., Ebbs, S., Micklem, K., Price, K., Gelber, R., and et al. (1994). "Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group." *Ann Oncol*, 5(5), 409-14.
- Neville, A. M., Bettelheim, R., Gelber, R. D., Save-Soderbergh, J., Davis, B. W., Reed, R., Torhorst, J., Golouh, R., Peterson, H. F., Price, K. N., and et al. (1992). "Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group [see comments]." *J Clin Oncol*, 10(5), 696-705.
- Nicolson, G. L. (1982). "Cancer Metastasis. Organ colonization and the cell-surface properties of malignant cells." *Biochem Biophys Acta*, 695, 113-176.
- Nieman, M. T., Prudoff, R. S., Johnson, K. R., and Wheelock, M. J. (1999). "N-cadherin promotes motility in human breast cancer cells regardless of their

E-cadherin expression.” *J Cell Biol*, 147(3), 631-44.

Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., Yamashita, H., Fukuda, M., and Higuchi, A. (1999). “Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis.” *J Surg Oncol*, 71(4), 226-34.

Nyström, L., Rutqvist, L. E., Wall, S., Lindgren, A., Lindqvist, M., Ryde'n, S., Andersson, I., Bjurstam, N., Fagerberg, G., Frisell, J., Tabar, L., and Larsson, L.-G. (1993). “Breast cancer screening with mammography overview of Swedish randomised trials.” *Lancet*, 341(8851), 973-978.

Obermair, A., Kurz, C., Hanzal, E., Bancher-Todesca, D., Thoma, M., Bodisch, A., Kubista, E., Kyrälä, E., Kaider, A., Sevelä, P., and et al. (1995). “The influence of obesity on the disease-free survival in primary breast cancer.” *Anticancer Res*, 15(5B), 2265-9.

Ochiai, A., Akimoto, S., Kanai, Y., Shibata, T., Oyama, T., and Hirohashi, S. (1994). “c-erbB-2 gene product associates with catenins in human cancer cells.” *Biochem Biophys Res Commun*, 205, 73-8.

Osborne, C. K., Yochmowitz, M. G., Knight, W. A., and McGuire, W. L. (1980). “The value of estrogen and progesterone receptors in the treatment of breast cancer.” *Cancer*, 46, 2884-8.

Paget, S. (1889). “Distribution of secondary growths in cancer of the breast.” *Lancet*, i, 5713.

Palmer, M. K., Lythgoe, J. P., and Smith, A. (1982). "Prognostic factors in breast cancer." *Br J Surgery*, 69(12), 697-8.

Papatestas, A. E., Miller, S. R., Pertsemlidis, D., Fagerstrom, R., Lesnick, G., and Aufses, A. H. (1986). "Association between prognosis and hormone receptors in women with breast cancer." *Cancer Detect Prev*, 9(3-4), 303-10.

Pascual, M. R., Macias, A., Moreno, L., and Lage, A. (1983). "Factors associated with prognosis in human breast cancer. III. Estradiol receptors and short term relapse." *Neoplasma*, 30(5), 589-92.

Pavelic, Z. P., Pavelic, L., Lower, E. E., Gapany, M., Gapany, S., Barker, E. A., and Preisler, H. D. (1992). "c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma." *Cancer Res*, 52(9), 2597-602.

Paydas, S., Sarpel, S., Gilman-Sachs, A., Tuncer, I., Pehlivan, S., Tunali, N., Zorludemir, S., Burgut, R., and Kucuk, O. (1994). "DNA ploidy, proliferative activity, and concanavalin A reactivity in breast cancer." *J Surg Oncol*, 56(1), 21-4.

Pereira, H., Pinder, S. E., Sibbering, D. M., Galea, M. H., Elston, C. W., Blamey, R. W., Robertson, J. F., and Ellis, I. O. (1995). "Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma." *Histopathology*, 27(3), 219-26.



- Pethe, V., and Shekhar, P. V. (1999). "Estrogen inducibility of c -Ha-ras transcription in breast cancer cells. Identification of functional estrogen-responsive transcription regulatory elements in exon 1/intron 1 of the c-Ha-ras gene." *J Biol Chem*, 274(43), 30969-78.
- Phillips, K. A., Andrulis, I. L., and Goodwin, P. J. (1999). "Breast carcinom arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? [see comments]." *J Clin Oncol*, 17(11), 3653-63.
- Piccart, M. (2001). "Closing remarks and treatment guidelines." *Eur J Cancer*, 37(1), S30-3.
- Pierceall, W. E., Woodard, A. S., Morrow, J. S., Rimm, D., and Fearon, E. R. (1995). "Frequent alterations in E-cadherin and a- and b-catenin expression in human breast cancer cell lines." *Oncogene*, 11, 1319-26.
- Pietilainen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V. M., and Syrjanen, K. (1996). "The important prognostic value of Ki -67 expression as determined by image analysis in breast cancer." *J Cancer Res ClinOncol*, 122(11), 687-92.
- Pinder, S. E., Ellis, I. O., Galea, M., O'Rourke, S., Blamey, R. W., and Elston, C. W. (1994). "Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up." *Histopathology*, 24(1), 41-7.
- Porter, P. L., El-Bastawissi, A. Y., Mandelson, M. T., Lin, M. G., Khalid, N., Watney, E. A., Cousens, L., White, D., Taplin, S., and White, E. (2000).

“Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- And screen-detected cancers.” *J Natl Cancer Inst*, 91(23), 2020-8.

Probst-Hensch, N. M., Pike, M. C., McKean-Cowdin, R., Stanczyk, F. Z., Kolonel, L. N., and Henderson, B. E. (2000). “Ethnic differences in post-menopausal plasma oestrogen levels: high oestrone levels in Japanese-American women despite low weight.” *Br J Cancer*, 82(11), 1867-70.

Railo, M., Nordling, S., Krogerus, L., Sioris, T., and vonSmitten, K. (1996). “Preoperative assessment of proliferative activity and hormonal receptor status in carcinoma of the breast : a comparison of needle aspiration and needle core biopsies to the surgical specimen.” *Cytopathology*, 15, 205-10.

Raju, U., and Vertes, D. (1996). “Breast papillomas with atypical ductal hyperplasia: a clinicopathologic study.” *Hum Pathol*, 27(11), 1231-8.

Rank, F., Dombernowsky, P., Jespersen, N. C., Pedersen, B. V., and Keiding, N. (1987). “Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial.” *Cancer*, 60(6), 1299-305.

Rasbridge, S. A., Gillett, C. E., Sampson, S. A., Walsh, F. S., and Millis, R. R. (1993). “Epithelial(E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma.” *J Pathol*, 169(2), 245-50.

Registry, F. C. (1996). “Cancer incidence in Finland 1994.” 57, Finnish Cancer Registry, the Institute for statistical and epidemiological cancer research,

Helsinki.

Reiner, A., Kolb, R., Reiner, G., Jakesz, R., Schemper, M., and Spona, J. (1987).

“Prognostic significance of steroid hormone receptors and histopathological characterization of human breast cancer.” *J Cancer Res Clin Oncol*, 113(3), 285-90.

Reiss, M. (1989). “Prognostic factors in primary breast cancer.” *Connecticut Medicine*, 53(10), 565-71.

Rizzieri, D. A., Vredenburgh, J. J., Jones, R., Ross, M., Shpall, E. J., Hussein, A., Broadwater, G., Berry, D., Petros, W. P., Gilbert, C., Affronti, M. L., Coniglio, D., Rubin, P., Elkordy, M., Long, G. D., Chao, N. J., and Peters, W. P. (1999). “Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.” *J Clin Oncol*, 17(10), 3064-74.

Rose'n, M., Lundin, A., Nyström, L., Rutqvist, L. E., Stenbeck, M., and Talbäck, M. (2000). “Incidence and mortality in breast cancer under 25 years. International and regional comparisons.” *Lakartidningen*, 97(1), 1-7.

Rosen, P. P., Groshen, S., and Kinne, D. W. (1992). “Survival and prognostic factors in node-negative breast cancer: results of long-term follow-up studies.” *J Natl Cancer Inst. Monographs*(11), 159-62.

Rosen, P. P., Saigo, P. E., Braun, D. W., Weathers, E., and Kinne, D. W. (1981).

“Prognosis in stage II (T1N1M0) breast cancer.” *Ann Surg*, 194(5), 576-84.

- Rosner, D., and Lane, W. W. (1993). "Predicting recurrence in axillary-node negative breast cancer patients." *Breast Cancer Res Treat*, 25(2), 127-39.
- Saez, S., Cheix, F., and Mayer, M. (1984). "Estrogen and progesterone receptors as prognostic factors in early breast cancer." *Recent Results Cancer Res*, 91, 192-8.
- Salami, N., Hirschowitz, S. L., Nieberg, R. K., and Apple, S. K. (1999). "Triple test approach to inadequate fine needle aspiration biopsies of palpable breast lesions." *Acta Cytol*, 43(3), 339-43.
- Sandri, M. I., Hochhauser, D., Ayton, P., Camplejohn, R. C., Whitehouse, R., Turley, H., Gatter, K., Hickson, I. D., and Harris, A. L. (1996). "Differential expression of the topoisomerase II alpha and beta genes in human breast cancers." *BJ Cancer*, 73(12), 1518-24.
- Sauer, R., Schauer, A., Rauschecker, H. F., Schumacher, M., Gatzemeier, W., Schmoor, C., Dunst, J., Seegenschmiedt, M. H., and Marx, D. (1992). "Therapy of small breast cancer: a prospective study on 1036 patients with special emphasis on prognostic factors [see comments]." *Int J Radiat Oncol Biol Phys*, 23(5), 907-14.
- Schaller, G., Bangemann, N., Becker, C., Buhler, H., Opri, F., and Weitzel, H. K. (1999). "Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein." *J Cancer Res Clin Oncol*, 125(8-9), 520-4.
- Schorr, K., Li, M., Krajewski, S., Reed, J. C., and Furth, P. A. (1999). "Bcl -2 gene

family and related proteins in mammary gland involution and breast cancer.” *J Mammary Gland Biol Neoplasia*, 4(2), 153-64.

Schumacher, M., Schmoor, C., Sauerbrei, W., Schauer, A., Ummenhofer, L., Gatzemeier, W., and Rauschecker, H. (1993). “The prognostic effect of histological tumor grade in node-negative breast cancer patients.” *Breast Cancer Res Treat*, 25(3), 235-45.

Sears, H. F., Janus, C., Levy, W., Hopson, R., Creech, R., and Grotzinger, P. (1982). “Breast cancer without axillary metastases. Are there high-risk biologic subpopulations?” *Cancer*, 50(9), 1820-7.

Senie, R. T., Lesser, M., Kinne, D. W., and Rosen, P. P. (1994). “Method of tumor detection influences disease-free survival of women with breast carcinoma.” *Cancer*, 73(6), 1666-72.

Sharifi, S., Peterson, M. K., Baum, J. K., Raza, S., and Schnitt, S. J. (1999). “Assessment of pathologic prognostic factors in breast core needle biopsies.” *Mod Pathol*, 12(10), 941-5.

Shek, L. L., and Godolphin, W. (1988). “Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis.” *Cancer Res*, 48(19), 5565-9.

Shih, C., Padhy, L. C., Murray, M., and Weinberg, R. A. (1981). “Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.” *Nature*, 290(5803), 261-4.

- Shih, C., Shilo, B. Z., Goldfarb, M. P., Dannenberg, A., and Weinberg, R. A. (1979). "Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin." *Proc Natl Acad Sci U S A*, 76(11), 5714-8.
- Silverstein, M. J., Lewinsky, B. S., Waisman, J. R., Gierson, E. D., Colburn, W. J., Senofsky, G. M., and Gamagami, P. (1994). "Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? [see comments]." *Cancer*, 73(6), 1673-7.
- Silverstein, M. J., Poller, D. N., Waisman, J. R., Colburn, W. J., Barth, A., Gierson, E. D., Lewinsky, B. S., Gamagami, P., and Slamon, D. J. (1995). "Prognostic classification of breast ductal carcinoma-in-situ." *Lancet*, 345, 1154-57.
- Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G., and Veronesi, U. (1993). "p53 as an independent prognostic marker in lymph node-negative breast cancer patients." *J Natl Cancer Inst*, 85(12), 965-70.
- Silvestrini, R., Daidone, M. G., Luisi, A., Boracchi, P., Mezzetti, M., Di Fronzo, G., Andreola, S., Salvadori, B., and Veronesi, U. (1995). "Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer." *J Clin Oncol*, 13(3), 697-704.
- Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. (1994). "The Bcl -2 protein: a prognostic indicator strongly related to p53 protein in lymph node-

negative breast cancer patients.” *J Natl Cancer Inst*, 86(7), 499-504.

Simpson, J. F., and Page, D. L. (1996). “The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer.” *Semin Oncol*, 23(4), 428-35.

Siziopikou, K. P., Prioleau, J. E., Harris, J. R., and Schnitt, S. J. (1996). “bcl -2 expression in the spectrum of preinvasive breast lesions.” *Cancer*, 77(3), 499-506.

Skoog, L., Wallgren, A., Pascual, M. R., Macias, A., Perez, R., and Lage, A. (1987). “Factors associated with prognosis in human breast cancer. VII. A comparison between a Cuban and a Swedish study.” *Neoplasma*, 34(5), 587-94.

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987). “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.” *Science*, 235(4785), 177-82.

Sledge, G. W., Jr., Hu, P., Falkson, G., Tormey, D., and Abeloff, M. (2000). “Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.” *J Clin Oncol*, 18(2), 262-6.

Snedeker, S. M., and Diaugustine, R. P. (1996). “Hormonal and environmental factors affecting cell proliferation and neoplasia in the mammary gland.” *Prog Clin Biol Res*, 394, 211-53.

- Speights, V. O., Jr. (1994). "Evaluation of frozen sections in grossly benign breast biopsies." *Mod Pathol*, 7(7), 762-5.
- Spiessl, B., Beahrs, O. H., and Hermanek, P. (1992a). "TNM Atlas. Illustrated guide to the TNM/pTNM classification of malignant tumours.", UICC, ed., Springer-Verlag, Berlin.
- Spiessl, O., Beahrs, O. H., Hermanek, P., Hutter, R. V. P., Scheibe, O., Sobin, L. H., and Wagner, G. (1992b). *TNM Atlas: Illustrated guide to the TNM/pTNM classification of malignant tumours*, Springer-Verlag, Heidelberg.
- Spratt, J. S. (2000). "Re: Dormancy of mammary carcinoma after mastectomy." *J Natl Ca Inst*, 92(13), 1101.
- Stanton, P. D., Cooke, T. G., Oakes, S. J., Winstanley, J., Holt, S., George, W. D., and Murray, G. D. (1992). "Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer [see comments]." *Br J Cancer*, 66(5), 925-9.
- Stierer, M., Rosen, H., Weber, R., Hanak, H., Spona, J., and Tuchler, H. (1993). "Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors." *Ann Surg*, 218(1), 13-21.
- Sunderland, M. C., and McGuire, W. L. (1990). "Prognostic indicators in invasive breast cancer." *Surg Clin North Am*, 70(5), 989-1004.



- Tabar, L. (1996). *Breast imaging and interventional procedures*, EAR teaching programmes, Turku.
- Takeichi, M. (1990). "Cadherins: A molecular family important in selective cell-cell adhesion." *Ann Rev Biochem*, 59, 237-52.
- Takeuchi, K., Yamaguchi, A., Urano, T., Goi, T., Nakagawara, G., and Shiku, H. (1995). "Expression of CD44 variant exons 8-10 in colorectal cancer and its." *Jpn J Cancer Res*, 86(3), 292-7.
- Teixeira, C., Reed, J. C., and Pratt, M. A. (1995). "Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells." *Cancer Res*, 55(17), 3902-7.
- Thomas, M., Noguchi, M., Fonseca, L., Kitagawa, H., Kinoshita, K., and Miyazaki, I. (1993). "Prognostic significance of Helix pomatia lectin and c-erbB-2 oncoprotein in human breast cancer." *Br J Cancer*, 68(3), 621-6.
- Thor, A. D., Liu, S., Moore II, D. H., and Edgerton, S. M. (1999). "Comparison of Mitotic Index, In Vitro Bromodeoxyuridine Labeling, and MIB-1 Assays to Quantitate Proliferation in Breast Cancer." *J Clin Oncol*, 17, 470-6.
- Tirkkonen, M., Tanner, M., Karhu, R., Kallioniemi, A., Isola, J., and Kallioniemi, O. P. (1998). "Molecular cytogenetics of primary breast cancer by CGH." *Genes Chromosomes Cancer*, 21, 177-84.
- Toikkanen, S., and Joensuu, H. (1990). "Prognostic factors and long-term survival

in breast cancer in a defined urban population.” *APMIS*, 98(11), 1005-14.

Toikkanen, S., Joensuu, H., and Klemi, P. (1989). “The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up.” *Br J Cancer*, 60(5), 693-700.

Toikkanen, S., and Kujari, H. (1989). “Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up.” *Hum Pathol*, 20(8), 758-64.

Tokuda, Y., Watanabe, T., Omuro, Y., Ando, M., Katsumata, N., Okumura, A., Ohta, M., Fujii, H., Sasaki, Y., Niwa, T., and Tajima, T. (1999). “Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.” *Br J Cancer*, 81(8), 1419-25.

Tominaga, S., and Kuroishi, T. (1999). “Epidemiology and Prevention of Breast Cancer in the 21st Century.” *Breast Cancer*, 6(4), 283-8.

Travis, A., Pinder, S. E., Robertson, J. F., Bell, J. A., Wencyk, P., Gullick, W. J., Nicholson, R. I., Poller, D. N., Blamey, R. W., Elston, C. W., and Ellis, I. O. (1996). “C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.” *Br J Cancer*, 74(2), 229-33.

Troncone, G., Zeppa, P., Vetrani, A., D'Arcangelo, A., Fulciniti, F., De Divitiis, B., and Palombini, L. (1995). “bcl-2 protein in breast cancer cells obtained by fine needle aspiration (FNA): a preliminary report.” *Cytopathology*,

6(4), 219-25.

Tsujimoto, Y., Cossman, J., Jaffe, E., and Croce, C. (1985). "Involvement of the bcl-2 gene in human follicular lymphoma." *Science*, 228, 1440-3.

Tubiana, M., Pejovic, M. H., Chavaudra, N., Contesso, G., and Malaise, E. P. (1984). "The long-term prognostic significance of the thymidine labelling index in breast cancer." *Int J Cancer*, 33(4), 441-5.

Tubiana, M., Pejovic, M. J., Renaud, A., Contesso, G., Chavaudra, N., Gioanni, J., and Malaise, E. P. (1981). "Kinetic parameters and the course of the disease in breast cancer." *Cancer*, 47(5), 937-43.

Ueno, T., Toi, M., and Tominaga, T. (1999). "Circulating soluble Fas concentration in breast cancer patients." *Clin Cancer Res*, 5(11), 3529-33.

Vakkala, M., Lahteenmaki, K., Raunio, H., Paakko, P., and Soini, Y. (1999). "Apoptosis during breast carcinoma progression." *Clin Cancer Res*, 5, 319-24.

Wallgren, A., Arner, O., Bergstrom, J., Blomstedt, B., Granberg, P. O., Raf, L., Silfversward, C., and Einhorn, J. (1986). "Radiation therapy in operable breast cancer: results from Stockholm trial on adjuvant radiotherapy." *int J Radiat Oncol Biol Phys*, 12(4), 533-7.

van Slooten, H. J., Clahsen, P. C., van Dierendonck, J. H., Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroide, A., van de Velde, C. J., and van de Vijver, M. J. (1996). "Expression of Bcl-2 in node-negative breast cancer

is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.” *Br J Cancer*, 74(1), 78-85.

Wang, T. T., and Phang, J. M. (1995). “Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7.” *Cancer Res*, 55(12), 2487-9.

Warri, A. M., Huovinen, R. L., Laine, A. M., Martikainen, P. M., and Harkonen, P. L. (1993). “Apoptosis in toremifene -induced growth inhibition of human breast cancer cells in vivo and in vitro.” *J Natl Cancer Inst*, 85(17), 1412-8.

Watson, D. M., Elton, R. A., Jack, W. J., Dixon, J. M., Chetty, U., and Miller, W. R. (1991). “The H-ras oncogene product p21 and prognosis in human breast cancer.” *Breast Cancer Res Treat*, 17(3), 161-9.

Watson, M., Haviland, J. S., Greer, S., Davidson, J., and Bliss, J. M. (1999). “Influence of psychological response on survival in breast cancer: a population-based cohort study.” *Lancet*, 354(9187), 1331-6.

Vaughn, J. P., Cirisano, F. D., Huper, G., Berchuck, A., Futreal, P. A., Marks, J. R., and Iglehart, J. D. (1996a). “Cell cycle control of BRCA2.” *Cancer Res*, 56(20), 4590-4.

Vaughn, J. P., Davis, P. L., Jarboe, M. D., Huper, G., Evans, A. C., Wiseman, R. W., Berchuck, A., Iglehart, J. D., Futreal, P. A., and Marks, J. R. (1996b). “BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.” *Cell Growth Different*, 7(6), 711-5.

- Veronesi, U., Galimberti, V., Zurrada, S., Merson, M., Greco, M., and Luini, A. (1993). "Prognostic significance of number and level of axillary node metastases in breast cancer." *The Breast*, 2, 224-8.
- Veronesi, U., Luini, A., Galimberti, V., Marchini, S., Sacchini, V., and Rilke, F. (1990). "Extent of metastatic axillary involvement in 1446 cases of breast cancer." *Eur J Surg*, 16, 127-33.
- Veronesi, U., Paganelli, G., Viale, G., Galimberti, V., Luini, A., Zurrada, S., Robertson, C., Sacchini, V., Veronesi, P., Oviato, E., DeCicco, C., Intra, M., Tosi, G., and Scarpa, D. (1999). "Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series." *J Natl Cancer Inst*, 91, 368-73.
- White, J., Levine, A., Gustafson, G., Wimbish, K., Ingold, J., Pettinga, J., Matter, R., Martinez, A., and Vicini, F. (1995). "Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy." *Int J Radiat Oncol Biol Phys*, 31(4), 791-7.
- Vicini, F. A., Goldstein, N. S., and Kestin, L. L. (1999). "Pathologic and technical considerations in the treatment of ductal carcinoma in situ of the breast with lumpectomy and radiation therapy." *Ann Oncol*, 10(8), 883-90.
- Vicini, F. A., Kestin, L. L., Goldstein, N. S., Chen, P. Y., Pettinga, J., Frazier, R. C., and Martinez, A. A. (2000). "Impact of young age on outcome in patients with ductal carcinoma-in- situ treated with breast-conserving therapy." *J Clin Oncol*, 18(2), 296-306.

Wilkinson, E. J., and Hendricks, J. B. (1993). "Fine needle aspiration of the breast for diagnosis of preinvasive neoplasia." *J Cellular Biochem - Suppl*, 17, 81-8.

Willsher, P. C., Pinder, S. E., Robertson, L., Nicholson, R. I., Ellis, I. O., Bell, J. A., Blamey, R. W., Green, J. A., and Robertson, J. F. (1996). "The significance of p53 autoantibodies in the serum of patients with breast cancer." *Anticancer Res*, 16(2), 927-30.

Winchester, D. P. (1991). "Adjuvant therapy for node -negative breast cancer. The use of prognostic factors in selecting patients." *Cancer*, 67(6 Suppl), 1741 - 3.

Visscher, D. W., Wallis, T. L., and Crissman, J. D. (1996). "Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics." *Cancer*, 77(2), 315-20.

Visscher, D. W., Wykes, S., Kubus, J., and Crissman, J. D. (1992). "Comparison of PCNA/cyclin immunohistochemistry with flow cytometric Sphase fraction in breast cancer." *Breast Cancer Res Treat*, 22(2), 111-8.

Witzig, T. E., Ingle, J. N., Cha, S. S., Schaid, D. J., Tabery, R. L., Wold, L. E., Grant, C., Gonchoroff, N. J., and Katzmann, J. A. (1994). "DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer." *Cancer*, 74(6), 1752-61.

Witzig, T. E., Ingle, J. N., Schaid, D. J., Wold, L. E., Barlow, J. F., Gonchoroff, N. J., Gerstner, J. B., Krook, J. E., Grant, C. S., and Katzmann, J. A. (1993).

“DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials.” *J Clin Oncol*, 11(2), 351-9.

Voelker, R. (2000). “Breast cancer vaccine.” *JAMA*, 284(4), 430.

Wohlfahrt, J., Andersen, P. K., Mouridsen, H. T., Adami, H. O., and Melbye, M. (1999). “Reproductive history and stage of breast cancer.” *Am J Epidemiol*, 150(12), 1325-30.

Wolberg, W. H., Street, W. N., and Mangasarian, O. L. (1999). “Importance of nuclear morphology in breast cancer prognosis.” *Clin Cancer Res*, 5(11), 3542-8.

Wood, W. C. (1994). “Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients.” *World J Surg*, 18(1), 39-44.

Wärnberg, F., Yuen, J., and Holmberg, L. (2000). “Risk of subsequent invasive breast cancer after breast carcinoma in situ.” *Lancet*, 355, 724-725.

Xing, W. R., Gilchrist, K. W., Harris, C. P., Samson, W., and Meisner, L. F. (1996). “FISH detection of HER -2/neu oncogene amplification in early onset breast cancer.” *Breast Cancer Res Treat*, 39(2), 203-12.

Yarbro, J. W., Page, D. L., Fielding, L. P., Partridge, E. E., and Murphy, G. P. (1999). “American Joint Committee on Cancer prognostic factors consensus conference [see comments].” *Cancer*, 86(11), 2436-46.

Zambelli, A., Da Prada, G. A., Pedrazzoli, P., Ponchio, L., and Robustelli della

Cuna, G. (1999). "Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment." *Anticancer Res*, 19(3B), 2373-6.

Zurrida, S., Morabito, A., Galimberti, V., Luini, A., Greco, M., Bartoli, C.,

Raselli, R., Rossi, N., Vessecchia, G., Cascinelli, N., and Veronesi, U.

(1999). "Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer." *Int J Oncol*, 15(3), 475-80.



